Áõ·Ê   Çлý¹ßÇ¥   °øÇØ   ¸é¿ªÄ¡·á   ÇÑÀÇÇп¡ ´ëÇÑ ³ªÀÇ ÀÌÇØ 
 
[¸ÞÀϸµ½Åû/Å»Åð]
  °íÁ¤°Ë»ö :  ¾Ë·¹¸£±â°³·Ð  /  ¾Ë·¹¸£°Õ  /  ±â°üÁöõ½Ä  /  ¾ÆÅäÇÇÇǺο°  /  À½½Ä¾Ë·¹¸£±â  /  µÎµå·¯±â  /  ¾Ë·¹¸£±âºñ¿° [ÃÖ½ÅÀÚ·á]
ÇöÀçÀ§Ä¡ : Çлý/Àü°øÀÇ ÀÚ·á
 
 Ãâ·Â    ¸ÞÀÏ    ¸®½ºÆ®    Ãßõ
2007³âµµ ¾Ë·¹¸£±â °³·Ð

ÀÔ·ÂÀÏ:2007-10-24 / ¼öÁ¤ÀÏ:2007-11-12 / Á¶È¸¼ö:72524 / Ãßõ¼ö:464 / ÀÛ¼ºÀÚ:drmesh

¾Ë·¹¸£±â °³·Ð ½Ã°£Àº ÀÇ°ú´ëÇлýµéÀÌ ¾Ë·¹¸£±â Çй®¿¡ óÀ½ Á¢Çϸ鼭 ¹è¿ì°Ô µÉ ±âº»ÀûÀÎ ¸é¿ªÇÐÀû, À¯ÀüÇÐÀû, ¼¼Æ÷ÇÐÀû ³»¿ëÀÇ ±âº»À» ´Ù½Ã Á¤¸®ÇÏ´Â ½Ã°£ÀÌ´Ù.À̸¦À§ÇØ ±âÃʸ鿪Çп¡ ´ëÇÑ ±âº»ÀûÀÎ Á¤º¸¸¦ ¾Ë°í ÀÖ¾î¾ß ÇÑ´Ù.

Á¤¸®ÇÑ ¼ø¼­´Â ´ÙÀ½°ú °°´Ù.

¾Ë·¹¸£±â °³·ÐÀÇ ÇнÀ¸ñÇ¥´Â ´ÙÀ½°ú °°´Ù.

¸é¿ªÇÐÀº ¹Ì»ý¹°ÀÇ ¹ß°ß°ú ´õºÒ¾î ½ÃÀ۵Ǿú´Ù.

    - ¸é¿ª°è´Â ´Ù¸¥ Çй®°ú °°ÀÌ ¸Å·ÂÀûÀÎ Çй®ÀÓ¿¡ Ʋ¸²¾ø´Ù. ¸é¿ªÇÐÀº 1796³â ¿µ±¹ÀÎÀÎ ¿¡µå¿öµå Á¨³Ê(Edward Jenner)°¡ ¿ìµÎ¹ÙÀÌ·¯½º(Cowpox)·Î õ¿¬µÎ(Smallpox)¸¦ ¿¹¹æÇÑ´Ù´Â º¸°í·Î ½ÃÀ۵Ǿú´Ù°í º¸Åë ¼³¸íÇÏ°í ÀÖ´Ù. ¿ø¸®´Â °£´ÜÇÏ´Ù. ¿ìµÎ¹ÙÀÌ·¯½º¸¦ »ç¶÷¿¡°Ô Åõ¿©ÇÏ¿´´õ´Ï õ¿¬µÎ°¡ °É¸®Áö ¾Ê¾Ò´Ù´Â °ÍÀÌ´Ù. À̸¦ Á¾µÎ¹ý(vaccination)À̶ó ºÒ·¶´Ù. Á¾µÎ¹ýÀº 100³â ÈÄ Áö¼®¿µÀÌ 1879³â ºÎ»ê¿¡ ÀÖ´Â ÀϺ»ÀÎ ÀÇ¿ø¿¡¼­ ¹è¿ö óÀ½ ½Ç½ÃÇÏ¿´À¸´Ï ¿ì¸®³ª¶óµµ ¸é¿ªÇÐÀÌ »ý±äÁö 100³â ÀÌ»óÀÌ È帥 °ÍÀÌ´Ù.

    - ÀÌÈÄ ÀÇÇа迡´Â µÎ ¸íÀÇ °ÅÀåÀ» ÅëÇؼ­ Çõ¸íÀûÀÎ º¯È­°¡ ÀϾ±â ½ÃÀÛÇÏ¿´´Ù . ÀÌ´Â ¹Ì»ý¹°ÀÇ ÀÚ¿¬ ¹ß»ý¼³À» ºÎÁ¤ÇÏ°í ±¤°ßº´ ¿¹¹æÁ¢Á¾À» ½ÃÇàÇÑ ÇÁ¶û½ºÀÎ ÆĽºÅð¸£(1908³â ·¯½Ã¾ÆÀÎ ¸ÞÄ¡´ÏÄÚÇÁ¿Í ÇÔ²² ³ëº§»ó)¿Í ÀÎü ƯÀÌÁúº´Àº ƯÁ¤ÇÑ ¹Ì»ý¹°¿¡ ÀÇÇÑ´Ù´Â °ÍÀ» Áõ¸íÇÑ µ¶ÀÏÀÎ ·Îº£¸£Æ® ÄÚÈå(1905³â °áÇÙ¿¡ ´ëÇÑ ¼¼Æ÷¸é¿ªÀ¸·Î ³ëº§»ó)ÀÌ´Ù.

    - ¹Ì»ý¹°ÀÇ ¹ß°ß¿¡ ÀÇÇؼ­ ¹Ì»ý¹°¿¡ ´ëÇÑ ÀÎü³» ¹ÝÀÀ¿¡ ´ëÇØ È®ÀÎÇÏ°íÀÚ ÇÏ´Â ¿¬±¸°¡ ÀÖ¾ú´Âµ¥ 1890³â µ¶ÀÏÀÎ ¿¡¹Ð º» º£¸µ(1901³â ³ëº§»ó)°ú ÀϺ»ÀÎ ½Ã¹Ù»çºÎ·Î ŰŸ»çÅä¿¡ ÀÇÇؼ­ ¡®¹é½ÅÁ¢Á¾À» ¹ÞÀº »ç¶÷ÀÇ Ç÷û¿¡´Â ±× º´¿øü¿¡¸¸ ƯÀÌÀûÀ¸·Î °áÇÕÇÏ´Â ¹°ÁúÀÌ Á¸ÀçÇÑ´Ù¡¯ ¶ó´Â »ç½ÇÀ» ¹ßÇ¥ÇÏ¿´°í ÀÌ°ÍÀ» ¡®Ç×ü¡¯¶ó°í ºÒ·¶´Ù.

    - ÀÌ·¸°Ô ÇÏ¿© Áö³­ 100¿©³â ÀüºÎÅÍ ¸é¿ªÇÐÀº ½ÃÀ۵Ǿú´Ù. À̹ø ½Ã°£¿¡´Â ¸é¿ªÇÐ ºÐ¾ß¿¡¼­ ¸é¿ª°úÀ×¹ÝÀÀ°ú ÀÎü³» ÀÚ°¡ ¹°Áú¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀ¿¡ ´ëÇÑ ºÐ¾ß¸¦ °øºÎÇÒ °ÍÀÌ´Ù.

ÀÎü°¡ Ç׿øÀ» ÀνÄÇÏ°í ¹ÝÀÀÇÏ´Â °ÍÀ» ¿¬±¸ÇÏ´Â °ÍÀÌ ¸é¿ªÇÐÀÇ ÇÙ½ÉÀÌ´Ù.

    - Ç׿ø (Antigen)À̶ó ÇÏ¸é ¹Ì»ý¹°À» Æ÷ÇÔÇÏ¿© ÀÎü ¼¼Æ÷°¡ ¹ÝÀÀÇÏ°Ô µÇ´Â ¸ðµç ¹°ÁúÀ» ¸»ÇÑ´Ù. À̶§ Ç×ü¸¦ »ý¼ºÇÏ°Ô µÈ´Ù. ¹Ì»ý¹°À̶ó Çϸé 4°¡Áö¸¦ ÁöĪÇϴµ¥ ÀÌ¿¡´Â ¼¼±Õ (Bacteria), ¹ÙÀÌ·¯½º (Virus), °õÆÎÀÌ (Fungus)¿Í ±â»ýÃæ (Parasite)ÀÌ ÀÖ´Ù. Ç׿øÀº Ç×ü¿Í ´ë¸³µÇ´Â °³³äÀÌÁö¸¸ Ç×ü »ý¼º ¾øÀÌ Æ÷½Ä¼¼Æ÷(Phagocyte cells)¿¡ ÀÇÇØ ¸ÔÈ÷°í ¼ÒÈ­µÇ±âµµ ÇÑ´Ù. À̸¦ ³»Àç¸é¿ª(Innate immune, ¼±Ãµ¸é¿ª)À̶ó°í ÇÑ´Ù. ÀûÀÀ¸é¿ª(Adaptive immune)Àº ƯÀÌ Ç׿ø¿¡ Ç×ü°¡ ¸¸µé¾îÁö°í ƯÁ¤ ¼¼Æ÷°¡ ´ëÀÀÇÏ´Â °ÍÀÌ´Ù. ³»Àç¸é¿ª°ú ÀûÀÀ¸é¿ªÀº ¸ðµÎ ¹éÇ÷±¸ÀÇ È°µ¿¿¡ ÀÇÇÑ °ÍÀÌ´Ù.

    - ¹Ì»ý¹°¿¡ ÀÇÇÑ °¨¿°¿¡ ´ëÇÑ ÀÎü ¹ÝÀÀÀ» ¡®°¨¿°-¸é¿ª¡¯À̶ó ÇÑ´Ù. ÀÌ´Â ±âÃʸ鿪½Ã°£¿¡ ¹è¿ì°Ô µÈ´Ù. ü³»¿¡ Á¾¾çÀÌ ¹ß»ýÇÏ¿´À» ¶§ Ç׿øÀ¸·Î ÀνÄÇÏ¿© ¹ÝÀÀÇÏ´Â °ÍÀ» ¿¬±¸ÇÏ´Â Çй®ÀÌ 'Á¾¾ç-¸é¿ª' ÀÌ´Ù. Á¤½Å ½Å°æ°è°¡ ¶ÇÇÑ ¸é¿ª°ú °ü·ÃÀÌ ÀÖ´Ù´Â °ÍÀÌ ÃÖ±Ù¿¡ ¹àÇôÁ³±â¿¡ À̸¦ ¡®Á¤½Å½Å°æ-¸é¿ª¡¯ Çй®À̶ó°í ÇÑ´Ù. ÀÚ±âÇ׿ø¿¡ ´ëÇØ ÀÚ±âÇ×ü¸¦ ¸¸µé¾î ³ªÅ¸³ª´Â º´ÀÌ 'ÀÚ°¡¸é¿ª' ÁúȯÀÌ°í ÀÌ´Â '¾Ë·¹¸£±â' Áúȯ °­ÀÇ°¡ ³¡³­ ÈÄ¿¡ °­ÀÇ°¡ À̾îÁú °ÍÀÌ´Ù.

    - ¾Ë·¹¸£±â ¹ÝÀÀÀ̶õ '¾Ë·¹¸£°Õ(¾Ë·¹¸£±âÇ׿ø)°ú °°Àº ºñÀÚ±â(non-self) ¹°Áú¿¡ ´ëÇÑ ¸é¿ªÇÐÀûÀÎ °ú¹Î¹ÝÀÀ'ÀÌ´Ù.

¸é¿ª ÀÌ»ó ¹ÝÀÀÀ» 1960³â´ë¿¡ ÇÑ ¿¬±¸ÀÚ°¡ 4°¡Áö·Î ºÐ·ùÇÏ¿´´Ù.

    - À̸¦ Coombs and Gell ºÐ·ù¶ó°í ÇÏ°í Áúº´ ±âÀüÀ» ÀÌÇØÇϴµ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ´Ù. 4°¡Áö·Î ºÐ·ùÇÏ¸ç °¢ Áúº´À» ÀÌÇØÇÏ°í ¿¹Á¦¸¦ ¾Ë°í ÀÖ¾î¾ß ÇÑ´Ù.

    - Type I (Á¦ 1Çü ¹ÝÀÀ) :

      ±âÀü : IgE ¸Å°³ Áï½Ã¹ÝÀÀ (IgE mediated acute reaction)

      Áúº´¸í : ±â°üÁö õ½Ä, µÎµå·¯±â, ¾Ë·¹¸£±â ºñ¿°, ¾ÆÅäÇÇ ÇǺο° °ú ¾Æ³ªÇʶô½Ã½º

      ±âÀü ¼³¸í : ºñ¸¸¼¼Æ÷ Ç¥¸é¿¡ IgE°¡ ºÙ¾îÀÖ°í ÀÌ°÷¿¡ ¾Ë·¹¸£°ÕÀÌ Á¢ÃËÇÏ¸é ¼¼Æ÷³» ½ÅÈ£Àü´Þ°úÁ¤À» ÅëÇØ ºñ¸¸¼¼Æ÷ ¶Ç´Â È£¿°±â±¸¿¡¼­ ¿©·¯ ¹°ÁúÀ» ºÐºñ, »ý»êÇس»¾î ³ª¿À´Â ¹ÝÀÀ

    - Type II (Á¦ 2Çü ¹ÝÀÀ) :

      ±âÀü : Ç×ü ÀÇÁ¸Çü ¹ÝÀÀ (Antibody dependent reaction)

      Áúº´¸í : ¼öÇ÷¹ÝÀÀ, ¿ëÇ÷¼º ºóÇ÷, Ç÷¼ÒÆÇ °¨¼ÒÁõ, Goodpasture Áúȯ, Æ÷â(pemphigus), ÁßÁõ±Ù¹«·ÂÁõ(myasthenia gravis), Thyroid toxicosis(Graves¡¯ disease)

      ±âÀü ¼³¸í : ¼¼Æ÷Ç¥¸é¿¡ µå·¯³ª ÀÖ´Â Ç׿ø±â(Antigenic determinants)¿Í Ç×ü(IgG ¶Ç´Â IgM)°¡ °áÇÕÇÏ¿© º¸Ã¼°è¸¦ È°¼ºÈ­ÇÏ¿© ¼¼Æ÷¿ëÇØ, »ç¸ê°úÁ¤À» ¹â°ÔµÇ´Â ¸é¿ª¹ÝÀÀÀ» ¸»ÇÑ´Ù.

    - Type III (Á¦ 3Çü ¹ÝÀÀ) :

      ±âÀü : ¸é¿ª º¹ÇÕü ¹ÝÀÀ ( Immune complex reaction)

      Áúº´¸í : Ç÷ûº´, Ç÷°ü¿°, »ç±¸Ã¼ ½Å¿°, Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶ÅäÀÌµå °üÀý¿°

      ±âÀü ¼³¸í : ¼¼Æ÷¿Ü¾×¿¡ Ç׿ø°ú Ç×ü°¡ °áÇÕÇÏ¿© Á¶Á÷¿¡ ħÂøÇÏ¿© µ¶¼ºÀ» ³ªÅ¸³»´Â ¸é¿ª¹ÝÀÀ.

    - Type IV (Á¦ 4Çü ¹ÝÀÀ) :

      ±âÀü : ¼¼Æ÷¸Å°³ Áö¿¬¹ÝÀÀ ( Cell mediated delayed type reaction)

      Áúº´¸í : Á¢Ã˼º ÇǺο°, °áÇÙ, ³ªº´, À̽İźÎ, °©»ó¼±¿°, ¾Ç¼ººóÇ÷, Á¦1Çü ´ç´¢

      ±âÀü ¼³¸í : T ¼¼Æ÷¿Í Ç׿øÀÌ Çùµ¿À¸·Î ¿©·¯ ÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸é¿ª¹ÝÀÀ.

        ±×¸²¼³¸í) ¸é¿ª¹ÝÀÀ 4°¡Áö¸¦ º¸¿©ÁÖ°í ÀÖ´Ù. Á¦ 1¹ÝÀÀÀÌ IgE ¸Å°³µÈ ¹ÝÀÀÀÌ°í Á¦ 2¹ÝÀÀÀº º¸Ã¼ ÀÛ¿ë¿¡ ÀÇÇÑ IgG, IgMÀÇ ¹ÝÀÀÀ» º¸ÀÌ°í ÀÖ´Ù. Á¦ 3¹ÝÀÀÀº Ç׿ø-Ç×ü ¹ÝÀÀÀÌ°í Á¦ 4¹ÝÀÀÀº T¼¼Æ÷ ¹ÝÀÀÀ» º¸¿©ÁØ´Ù.

Á¦ 1Çü ¹ÝÀÀÀ̶õ IgE¸¦ ¸Å°³ÇÏ´Â ¹ÝÀÀÀ» ¸»ÇÑ´Ù.

    - °¡Àå ¸¹ÀÌ ¾Ë·ÁÁø ¹ÝÀÀÀÌ´Ù. ¸ÕÀú ¾Ë·¹¸£°Õ¿¡ ³ëÃâµÇ¾î Àνĵǰí IgE°¡ ¸¸µé¾îÁø´Ù. À̴ ǥÀûÁ¶Á÷ÀÇ ºñ¸¸¼¼Æ÷(mast cell)³ª È£¿°±â±¸(Basophil)¿¡ µé¾îºÙ¾î ÀÖ´Ù°¡ »õ·Ó°Ô Ç׿ø¿¡ ³ëÃâÀÌ µÇ¸é ¼¼Æ÷¿¡¼­ ¿©·¯ È­Çй°ÁúÀ» ½ñ¾Æ³»¹Ç·Î¼­ ¹ÝÀÀÀÌ ÀϾ´Â °ÍÀÌ´Ù. ÀÌ·¯ÇÑ Áúº´¿¡´Â ±â°üÁö õ½Ä, µÎµå·¯±â, ¾Ë·¹¸£±â ºñ¿°, ¾ÆÅäÇÇ ÇǺο°°ú ¾Æ³ªÇʶô½Ã½º°¡ ÀÖ´Ù.

    - ¾Ë·¹¸£±â ºñ¿°¿¡ ´ëÇØ »ý°¢Çغ¸ÀÚ. ¾î¶² »ç¶÷ÀÌ °õÆÎÀÌ Æ÷ÀÚ(Asp f 1)¿¡ ÀÇÇØ ºñ¿°ÀÌ ¾ÇÈ­µÈ´Ù. ±×´Â ÀÚµ¿Â÷¿¡ Ÿ±â¸¸ Çϸé Ä๰ÀÌ ³ª°í Àçä±â¸¦ ÇÑ´Ù. Ç㱸ÇÑ ¿©¸§³¯¿¡µµ ±×´Â ÄÚ ¸·Çô¼­ °¨±â¾Î´À³Ä´Â ¼Ò¸®¸¦ ÀÚÁÖ µè´Â´Ù. ¾î´À³¯ Ä£±¸¸¦ ¸¸³ª±â À§ÇÏ¿© ÁöÇÏöÀ» Ÿ°Ô µÇ¾ú´Ù. ÁöÇÏö¿¡´Â °õÆÎÀÌ°¡ ¸¹ÀÌ ºÎÀ¯ÇÑ´Ù´Â ´º½º°¡ ÀÖ¾ú´Ù. ÁöÇÏöÀ» Ÿ°í °¡´Ù ±×´Â Ä๰°ú Àçä±â, ÄÚ°¡ °£Áö·¯¿òÀ» ´À²¼´Ù. ÀÌ·± »óȲ¿¡¼­ ¸é¿ªÇÐÀûÀ¸·Î ±×ÀÇ ÄÚ¿¡¼­´Â ¾î¶² ¹ÝÀÀÀÌ ÀϾÀ»±î ?

    - À̸¦ ü³»¿¡¼­ Ç׿ø°ú Ç×üÀÇ ¹ÝÀÀÀ» ¼³¸íÇÏ¸é ´ÙÀ½°ú °°´Ù.

    - °ø±â Áß¿¡´Â ¸¹Àº ¼öÀÇ ¾Ë·¹¸£°Õ°ú ¹ÙÀÌ·¯½º, ¼¼±ÕµéÀÌ µ¹¾Æ´Ù´Ñ´Ù. ÀÌ Áß¿¡´Â °õÆÎÀÌ¿¡¼­ ¶³¾îÁ® ³ª¿Â Æ÷ÀÚ°¡ ÀÖ°í °ø±â Áß¿¡ ºÎÀ¯ÇÏ´ø °õÆÎÀÌ Æ÷ÀÚ°¡ ¼ûÀ» ½¬´Â ¾Ë·¹¸£±â ºñ¿°À» ¾Î´Â »ç¶÷ÀÇ ÄÚ Á¡¸·¿¡ ´Þ¶óºÙ°Ô µÈ´Ù. ÄÚ Á¡¸·¿¡´Â ¸¹Àº ¼öÀÇ ºñ¸¸¼¼Æ÷°¡ ÀÖ´Ù. ÀÌ ¼¼Æ÷¿¡ ºÙ¾îÀÖ´ø Ç×üÀÇ ÀÏÁ¾ÀÎ IgE´Â Áï½Ã °õÆÎÀÌ Æ÷ÀÚ¿¡ ´ëÇØ ¹Î°¨ÇÏ°Ô ¹ÝÀÀÀ» º¸ÀÌ°Ô µÈ´Ù. IgE°¡ ¼­·Î ±³Â÷¹ÝÀÀÀÌ ÀϾ¸ç ºñ¸¸¼¼Æ÷³»·Î ½ÅÈ£Àü´ÞÀ» ÇÑ´Ù. °õÆÎÀÌ Æ÷ÀÚ¸¦ ÅðÄ¡Çϱâ À§ÇØ ºñ¸¸¼¼Æ÷´Â ¹Ù·Î È­Çй°ÁúÀ» ºÐºñÇÒ °ÍÀÌ´Ù. ÀÌ¿¡´Â Ä๰°ú Àçä±â¸¦ À¯¹ßÇÏ´Â È÷½ºÅ¸¹Î°ú ·ùÄÚÆ®¸®¿£°ú °°Àº È­Çй°ÁúÀÌ Æ÷ÇԵȴÙ.

    - ÀÌ·± È­Çй°ÁúÀ» ¾ïÁ¦ÇÏ´Â ¾àÀÌ °¨±â¾à¿¡ ¾²ÀÌ´Â Ç× È÷½ºÅ¸¹ÎÁ¦Àç¿Í ¾Ë·¹¸£±â ºñ¿°¿¡ ¾²ÀÌ´Â Ç×·ùÄÚÆ®¸®¿£ ¾àµéÀÌ´Ù. ÄÚ Á¡¸·¿¡ º¸ÀÌÁö ¾Ê´Â È­Çй°ÁúÀÇ ÀÌ·¯ÇÑ °©ÀÛ½º·±(Æø¹ßÀûÀÎ) ºÐºñ·Î ÀÎÇØ, ´çȲÇÑ ±×´Â ÇÑ ¼Õ¿¡ Ƽ½´¸¦ ¿õÄÑÁã°í ÄÚ¸¦ ÈǽÀ̸ç Ä£±¸¸¦ ¸¸³ª°Ô µÈ´Ù.

Á¦ 2Çü ¹ÝÀÀÀº ¼¼Æ÷µ¶¼º °ú¹Î¹ÝÀÀÀÌ´Ù.

    - ¼¼Æ÷Ç¥¸é¿¡ Ç׿ø (Antigenic determinants) ÀÌ ³ëÃâµÇ¾î ÀÖ´Ù¸é Ç×ü°¡ À̸¦ ÀνÄÇÏ°Ô µÇ°í º¸Ã¼°è°¡ È°¼ºÈ­µÇ¾î Ç׿øÀÌ Ç¥½ÃµÇ¾î ÀÖ´Â ¼¼Æ÷¸¦ ½Ä±ÕÀÛ¿ëÀ̳ª NK ¼¼Æ÷·Î Á×ÀÌ´Â ¹ÝÀÀÀÌ´Ù. ÀÌ¿¡ °ü¿©ÇÏ´Â Ç×ü´Â IgG ¶Ç´Â IgM ÀÌ´Ù. µå¹°°Ô IgA°¡ °ü¿©¸¦ ÇÑ´Ù. ¸¸ÀÏ Ç׿øÀÌ ÀûÇ÷±¸¿¡ ÀÖ´Ù¸é ÀûÇ÷±¸°¡ ±úÁö¸é¼­ ¿ëÇ÷ÀÌ ÀϾ °ÍÀÌ°í, Ç÷¼ÒÆÇ¿¡ ÀÖ´Ù¸é Ç÷¼ÒÆÇ °¨¼ÒÁõÀÌ ÀϾ °ÍÀÌ´Ù. ÀÌ·¯ÇÑ ±âÀü¿¡ ÀÇÇÑ Áúº´¿¡´Â ¼öÇ÷¹ÝÀÀ, ¿ëÇ÷¼º ºóÇ÷ , Ç÷¼ÒÆÇ °¨¼ÒÁõ, Goodpasture Áúȯ, õÆ÷â(pemphigus), ÁßÁõ±Ù¹«·ÂÁõ(myasthenia gravis), Thyroid toxicosis(Graves¡¯ disease) °¡ ÀÖ´Ù.

    - ¿¹¸¦ ¼öÇ÷ ºÎÀÛ¿ëÀ» µé¾îº¸ÀÚ. AÇüÀÎ »ç¶÷ÀÌ BÇüÀÎ »ç¶÷¿¡°Ô¼­ ¼öÇ÷À» ¹Þ°Ô µÇ¸é BÇü ÀûÇ÷±¸¿¡ ³ªÅ¸³­ BÇü Ç׿øÀ» AÇü Ç÷û¿¡ ÀÖ´Â BÇü Ç×ü°¡ ÀνÄÇÏ°í ÀÌ¿¡ º¸Ã¼°è°¡ È°¼ºÈ­µÇ¾î ÀϾ°Ô µÈ´Ù.

    - Goodpasture ÁõÈıºÀº ±âÀú¸·(basement membrane)ÀÇ Á¦4Çü Äݶó°Õ a3 »ç½½¿¡ ´ëÇÑ Ç×ü°¡ »ý°Ü ÀÌ Ç×ü°¡ ½Å »ç±¸Ã¼ ±âÀú¸·À̳ª ÆóÆ÷ ±âÀú¸·¿¡ °áÇÕÇÏ¿© ¿°Áõ¹ÝÀÀÀ» ÀÏÀ¸Å²´Ù.

    - ¼ö¿ëü¿¡ ´ëÇÑ ÀÚ°¡Ç×ü°¡ ¸¸µé¾îÁö¾î ¼ö¿ëüÀÇ ±â´ÉÀ» ÀÚ±ØÇϰųª ¾ïÁ¦ÇÏ¿© ÁúȯÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ ¼ö¿ëüÀÇ Ç×ü°¡ ±æÇ×Á¦ (antagonist) ¶Ç´Â ÀÛ¿ëÁ¦(agonist) ¿ªÇÒÀ» ÇÒ ¼ö ÀÖÀ¸¸ç À̸¦ µû·Î ºÐ·ùÇϱ⵵ ÇÑ´Ù(II b ¶Ç´Â Type 1/7 ; 4°¡Áö ºÐ·ù¿¡¼­´Â IIa/IIb·Î ³ª´µ°í À̸¦ IIb·Î Çϸç, ¸é¿ª¹ÝÀÀÀ» 7°¡Áö Á¾·ù·Î ³ª´­ ¶§¿¡´Â Type 1 ÀÓÀ» ÀǹÌÇÑ´Ù. ÀÌ¿¡´ëÇÑ ÀÚ¼¼ÇÑ ¼³¸íÀº '¸é¿ª¹ÝÀÀÀ» 7Á¾·ù·Î ¼¼ºÐÇÒ ¼ö ÀÖ´Ù' Ç׸ñÀ» º¸¶ó).

    ÀÌ¿¡´Â Graves Áúȯ, ÁßÁõ±Ù¹«·ÂÁõ, Àν¶¸° ÀúÇ×¼º ´ç´¢º´ (Insulin resistant Diabetes), Hypoglycemia ¿Í ÀϺΠ¸¸¼º µÎµå·¯±â°¡ ÀÖ´Ù.

    - Graves ÁúȯÀº TSH ¼ö¿ëü¿¡ ´ëÇÑ ÀÚ°¡ Ç×ü·Î °©»ó¼± ±â´É Ç×ÁøÁõÀÌ ³ªÅ¸³­´Ù.

    - ÁßÁõ±Ù¹«·ÂÁõ (Myasthenia gravis)Àº NM Á¢ÇÕºÎÀ§¿¡ Á¸ÀçÇÏ´Â ´ÏÄÚƾ ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëüÀÇ ¥á »ç½½¿¡ ´ëÇÑ ÀÚ°¡ Ç×ü°¡ »ý°Ü¼­ ½ÅÈ£Àü´ÞÀÌ ¾ïÁ¦µÇ°í ±Ù ¹«·ÂÁõÀÌ ³ªÅ¸³ª´Â °ÍÀÌ´Ù.

    - Àν¶¸° ÀúÇ×¼º ´ç´¢º´(Type IIb)Àº Àν¶¸° ¼ö¿ëü¿¡ ´ëÇÑ ±æÇ×Á¦°¡, ÀúÇ÷´çÁõÀº Àν¶¸°Ç×ü ÀÛ¿ëÁ¦°¡ ¹ßÇöµÈ °ÍÀÌ´Ù.  ¸¸¼º µÎµå·¯±â ÀϺΠȯÀÚ¿¡¼­´Â FceRI-¥áÀÇ ÀÚ°¡Ç×ü IgG°¡ ¸¸µé¾îÁö¾î ÀÌ Ç×ü°¡ ºÐºñ¸¦ Áõ°¡½ÃÄÑ ¹ÝÀÀÀÌ ÀϾ´Ù.

      - Ç×ü ¸Å°³ ¼¼Æ÷µ¶¼º¹ÝÀÀ (IIa)

      • º¸Ã¼ È°¼ºÈ­¸¦ ÅëÇÑ Opsonization,
      • º¸Ã¼ Membrane attack complex(MAC ; C5-9)¿¡ ÀÇÇÑ ¿ëÇ÷ÀÛ¿ë(lysis)
      • ADCC(Antibody dependent cell mediated cytotoxicity)

      - »ý¹°ÇÐÀû(biological) ±â´ÉÀ» °¡Áø ºÐÀÚ µéÀÇ ÀÛ¿ëÁ¦, ±æÇ×Á¦ ¿ªÇÒ(IIb, 1/7)

      • ÀÛ¿ëÁ¦ : ÀúÇ÷´çÁõ, ¸¸¼ºµÎµå·¯±â ÀϺÎ, Graves disease
      • ±æÇ×Á¦ : Type IIb ´ç´¢º´, ÁßÁõ±Ù¹«·ÂÁõ

    - OpsonizationÀ̶õ 20¿©°³ÀÇ º¸Ã¼°¡ ¿¬¼âÀûÀ¸·Î ÀÛ¿ëÇÏ¿© Ç׿øÀ» µÑ·¯½Ñ ÈÄ ´ë½Ä¼¼Æ÷ÀÇ C3b ¼ö¿ëü¿Í °áÇÕÇÏ¿© Ç׿øÀ» ºÐÇØÇϱ⠽±µµ·Ï ÇÏ´Â ÀÛ¿ë. ¿¹¸¦µé¾î Ç÷¼ÒÆÇ °¨¼ÒÁõ ȯÀÚ¿¡¼­ Ç÷¼ÒÆÇ¿¡ Ç×ü°¡ ºÙ°í ÀÌ¿¡ º¸Ã¼°¡ ÀÛ¿ëÇÏ¿© ´ë½Ä¼¼Æ÷ ÀÛ¿ëÀ¸·Î Ç÷¼ÒÆÇÀ» ¾ø¾Ö´Â ±âÀü.

    - ¿ëÇ÷ÀÛ¿ë(Cell lysis)¶õ º¸Ã¼°¡ È°¼ºÈ­µÇ°í º¸Ã¼ MAC ÀÛ¿ëÀ¸·Î ¼¼Æ÷¿¡ ±¸¸ÛÀ» ¶Õ¾î¼­ ¼¼Æ÷¸¦ Á×ÀÌ´Â ÀÛ¿ëÀÌ´Ù. ¿¹¸¦µé¾î ÀûÇ÷±¸¿¡ Æä´Ï½Ã¸°ÀÌ ºÙ¾î ÀÖ°í Anti-penicilloyl Ç×ü°¡ ºÙ°í ÀÌ¿¡ µû¶ó º¸Ã¼°¡ È°¼ºÈ­µÇ¸ç MAC ÀÛ¿ëÀ¸·Î ÀûÇ÷±¸¸¦ Æı«½ÃÅ°´Â ÀÛ¿ëÀÌ´Ù. À̸¦ Penicillin-induced autoimmune hemolytic anemia ¶ó ÇÑ´Ù.

    - ADCC ÀÛ¿ëÀ̶õ Ç׿ø°ú Ç×ü°¡ ºÙ°í º¸Ã¼°¡ È°¼ºÈ­µÇ¾î NK¼¼Æ÷³ª ´ë½Ä¼¼Æ÷ÀÇ ÀÛ¿ë¿¡ ÀÇÇØ Cell¿¡ Toxicity¸¦ ÁÖ¾î ÀÛ¿ëÇÑ´Ù. ¿¹¸¦µé¾î °©»ó¼± Áúȯ¿¡¼­´Â Ç×°©»ó¼±Ç×ü(anti thyroid Ab)¿¡ Ç×ü°áÇÕ¹ÝÀÀÀ» ÇÏ¿© °©»ó¼±¿°À» ÀÏÀ¸Å²´Ù. ¶Ç ´Ù¸¥ ¿¹·Î´Â ±â»ýÃæÀÌ Ä§¹üÇÏ¿´À» ¶§ ±â»ýÃæ¿¡ IgG°¡ ºÙ°í ÀÌ¿¡´ëÇÑ FcgRII¸¦ °¡Áø È£»ê±¸°¡ °áÇÕÇÏ¿© ±â»ýÃæ¿¡ µ¶¼º ÀÛ¿ëÀ» ÇÏ´Â °ÍÀÌ´Ù.

     

Á¦ 3Çü ¹ÝÀÀÀº ¸é¿ªº¹ÇÕü(Ç׿ø/Ç×ü) ¹ÝÀÀÀÌ´Ù.

    - Ç׿ø°ú Ç×ü°¡ °áÇÕÇÏ¿© Á¶Á÷¿¡ ħÂøÇÏ¿© µ¶¼ºÀ» ³ªÅ¸³»´Â ¸é¿ª¹ÝÀÀÀÌ´Ù. ÀÌ¿¡´Â Ç÷ûº´, Ç÷°ü¿°, »ç±¸Ã¼ ½Å¿°°ú Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶ÅäÀÌµå °üÀý¿°°ú °°Àº ÀÚ°¡¸é¿ªÁúȯÀÌ ¼ÓÇÑ´Ù.

    - °¡Àå ¸¹ÀÌ ¾Ë·ÁÁø ¹ÝÀÀÀº ¡®Ç÷ûº´(Serum sickness)¡¯ ÀÌ´Ù.

    - ü³»¿¡ ÀÌÁúÀûÀÎ ´Ü¹éÁúÀ̳ª Ç÷ûÀ» ÅõÀÔÇϸé ÀÌ¿¡ ´ëÇÑ Ç×ü°¡ »ý¼ºµÇ°í ÀÌ Ç׿ø-Ç×ü °áÇÕü°¡ Á¶Á÷¿¡ ħÂøµÇ¾î º´À» ÀÏÀ¸Å°´Â °ÍÀÌ´Ù. Ç÷ûº´Àº Pirquet °ú SchickÀÌ µðÇÁÅ׸®¾Æ¸¦ Ä¡·áÇϱâ À§ÇØ ¸»¿¡´Ù µðÇÁÅ׸®¾Æ µ¶¼Ò¸¦ ÁÖ»çÇÏ°í ÀÌ¿¡´ëÇÑ Ç×ü¸¦ ¾ò¾î ÀÎü¿¡ Åõ¿©ÇÑ ÈÄ Áõ»óÀÌ ¹ßÇöµÇ¾î ±â¼úÇϸ鼭 ¾Ë·ÁÁ³´Ù.

    - 1900³â´ë ÃÊ ¹é½ÅÀ̶ó´Â °³³äÀÌ ¾î¼³ÇÁ°Ô ¼Ò°³µÇ¸é¼­ ¸¹Àº ÀÇ»çµéÀº °¨¿°º´À» Á¶ÀýÇϱâ À§Çؼ­ Á¾µÎ¹ý°ú °°Àº ¹æ¹ýÀ¸·Î ¹é½ÅÁ¦Á¶ ÇÏ°í Ä¡·á¸¦ ÇÏ¿´´Ù. ÀÌ¿¡´Â ÇÊ¿¬ÀûÀ¸·Î ÀÌÁ¾ ´Ü¹éÁúÀ̶ó°í ÇÒ ¼ö ÀÖ´Â µ¿¹° Ç÷ûÀÌ »ç¿ëµÇ¾ú°í ´ç½Ã 25% ÀÌ»óÀÇ ½É°¢ÇÑ ºÎÀÛ¿ë°ú »ç¸Á·üÀ» ±â·ÏÇÏ°Ô µÈ´Ù.

    - ÀÌ·¯ÇÑ º¹ÇÕü°¡ Ç÷°ü¿¡ ħÂøÇϸé Ç÷°ü¿°ÀÌ »ý±â°Ô µÇ°í ÄáÆÏ¿¡¼­´Â »ç±¸Ã¼ ½Å¿° ÀÌ »ý±â°Ô µÈ´Ù. °üÀý¿¡µµ »ý±â°í ÇǺθ¦ ºñ·ÔÇÑ Àü½Å¿¡ Áõ»óÀÌ ³ªÅ¸³ª°Ô µÈ´Ù. ÀÌ·¯ÇÑ ¸é¿ªº¹ÇÕü´Â ½±°Ô Æ÷½Ä¼¼Æ÷¿¡ ÀÇÇؼ­ Á¦°ÅµÇ´Âµ¥ ´Ù·®ÀÇ Ç׿øÀÌ µé¾î¿Ô°Å³ª Ç׿øÀÌ Á¦°ÅÇϴµ¥ ½ÇÆÐÇÏ¿© Áö¼ÓÀûÀ¸·Î Ç׿øÀÌ Ã¼³»¿¡ Á¸ÀçÇÒ ¶§ Ç÷ûº´ÀÌ ÀϾ°Ô µÈ´Ù.

    - ¿¹¸¦ µé¾î ¼¼±Õ¼º ½É³»¸·¿°°ú ¸¸¼º ¹ÙÀÌ·¯½º¼º °£¿°ÀÌ Ç÷ûº´°ú ºñ½ÁÇÑ Áõ¼¼°¡ ³ªÅ¸³ª°Ô µÈ´Ù. ¶ÇÇÑ ÀÚ°¡ ¸é¿ªÁúȯÀÎ Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢°ú ·ù¸¶ÅäÀÌµå °üÀý¿°µµ ÀÌ¿Í °°Àº ¸é¿ª±âÀü¿¡ ÀÇÇÏ¿© Áõ»óÀÌ ¹ßÇöµÈ´Ù. ÀϺΠÈíÀÔ ¾Ë·¹¸£°Õ¿¡ ÀÇÇؼ­ IgG ¹ÝÀÀÀÌ ÀϾ°Ô µÇ´Âµ¥ ÆóÀÇ ÆóÆ÷º®¿¡ ¸é¿ªº¹ÇÕü°¡ Çü¼ºµÇ¾î Æó±â´É¿¡ ¹®Á¦¸¦ ¹ß»ý½ÃŲ´Ù. ÀÌ¿¡´Â ³óºÎÆó(Farmer¡¯s lung)¿Í °°Àº °ú¹Î¼º ÆóÀå¿° ÀÌ ¼ÓÇÑ´Ù.

    - ±¹¼ÒÀûÀÎ Ç÷ûº´ÀÇ ¸ðµ¨·Î´Â Arthus reaction ÀÌ ÀÖ´Ù. ÇǺο¡ Ç׿øÀ» ÁÖÀÔÇϸé Ç×ü¿Í ÇÔ²² ¸é¿ª º¹ÇÕü¸¦ Çü¼ºÇÏ°í º¸Ã¼°¡ È°¼ºÈ­µÇ°í ¹éÇ÷±¸ÀÇ Fc ¼ö¿ëü¿¡ ºÎÂøµÇ¾î ¹éÇ÷±¸¿¡¼­ È­Çй°ÁúÀÌ ºÐºñµÇ¾î ±¹¼ÒÀû ¿°Áõ ¹ÝÀÀÀÌ ÀϾ¸ç ÁÖ»çÇÑ ÀÚ¸® ±Ùó¿¡ ÀÛÀº µ¿¸Æ¿¡ Ç÷°ü¿°ÀÌ »ý±â´Â °ÍÀÌ´Ù.

    ½ÉÈ­ÇнÀ

    - Rh À½¼ºÀÎ »ê¸ð¿¡°Ô¼­ ù¹ø° ¾ÆÀÌ°¡ Rh ¾ç¼ºÀÎ ¾ÆÀÌ°¡ ž´Ù¸é µÎ¹ø° ¾ÆÀÌ°¡ ž ¶§ ¾î¶² ¹ÝÀÀÀÌ ÀϾ´Â°¡ ? ÀÌ·¸°Ô ÇÏ¿© ¾ÆÀ̸¦ ÀÒ´Â °ÍÀ» žÆÀû¾Æ±¸Áõ (÷Ãä®îåä´Ï¹ñø ; Erythroblastosis fetalis)À̶ó°í ÇÑ´Ù.

    - ÇÑ ¾ÆÀÌ°¡ °¨±â¿¡ °É¸° ÈÄ Post-streptococcal glomerulonephritis (APSGN)¿¡ °É¸®¾ú´Ù. ±âÀüÀ» ¼³¸íÇ϶ó.

Á¦ 4Çü ¹ÝÀÀÀº ¼¼Æ÷¸Å°³ Áö¿¬¼º ¸é¿ª¹ÝÀÀÀÌ´Ù.

    - ¿ÜºÎÇ׿øÀ» T ¼¼Æ÷°¡ ÀνÄÇÏ¿© ÀϾ´Â ¸é¿ª¹ÝÀÀÀ» ¸»ÇÑ´Ù. ÀÌ´Â B¼¼Æ÷¸¦ ÅëÇÑ Ç×ü¿Í °ü·ÃÀÌ ¾ø±â¿¡ ¼¼Æ÷¸Å°³¸é¿ª¹ÝÀÀ (Cell mediated reaction) À̶ó ºÒ¸°´Ù. Ç׿øÀÌ µé¾î¿À¸é ƯÀÌ T¼¼Æ÷¸¦ ¸¸µé±â À§ÇÑ ºÐÈ­, ºÐ¿­¿¡ ½Ã°£ÀÌ ÇÊ¿äÇϸç, ¸é¿ª¹ÝÀÀÀÌ ÀϾ±â À§Çؼ­´Â ¸çÄ¥ÀÌ ¼Ò¿äµÇ±â¿¡ Áö¿¬¼º ¸é¿ª¹ÝÀÀ (Delayed type reaction)À̶ó°íµµ ÇÑ´Ù.

    - °¡Àå ÈçÇÑ ¹ÝÀÀÀÇ ÁöÇ¥´Â °áÇÙ¿¡ ´ëÇÑ Æ©¹öŬ¸° ¹ÝÀÀ(Tuberculin reaction)ÀÌ´Ù. À̸¦ Çؼ®Çϴµ¥ 48-72½Ã°£ÀÌ ÇÊ¿äÇÏ´Ù.

    - ÇǺο¡ °áÇÙ ´Ü¹éÁúÀ» ¼Ò·® ÅõÀÔÇϸé À̸¦ ¾ø¾Ö±â À§ÇØ ¶û°Ô¸£Çѽº¿Í °°Àº ¼öÁö»ó¼¼Æ÷°¡ ±¹¼Ò ¸²ÇÁÀý·Î À̵¿ÇÏ¿© T¼¼Æ÷¿¡ Ç׿øÀ» Àü´ÞÇÏ°Ô µÇ°í È°¼ºÈ­µÈ T¼¼Æ÷°¡ ±¹¼ÒºÎÀ§·Î À̵¿ÇÏ¿© Ç׿øÀ» ¾ø¾Ö±âÀ§ÇÑ ¹ÝÀÀÀ» º¸ÀÌ°Ô µÈ´Ù. ÀÌ·± ¹ÝÀÀÀ» º¸ÀÌ´Â ´ëÇ¥ÀûÀÎ ÁúȯÀ¸·Î´Â Á¢Ã˼º ÇǺο°, °áÇÙ, ³ªº´(ÇѼ¾º´), À̽İźÎ, °©»ó¼±¿°, ¾Ç¼ººóÇ÷, Á¦1Çü ´ç´¢°¡ ÀÖ´Ù.

    - °¡Àå ÈçÇÏ°Ô ¼³¸íÇÏ°í ¹ß»ýÇÏ´Â °ÍÀº ¿Ì³ª¹«(Ivy)¿¡ ÀÇÇÑ Á¢Ã˼º ÇǺο°ÀÌ´Ù. ÀÌ µ¶¼º¹°ÁúÀÌ ÇǺο¡ ´êÀ¸¸é Th1¼¼Æ÷ ¹ÝÀÀÀÌ ÁÖ·Î ¿°Áõ¹ÝÀÀ¿¡ ±â¿©ÇÏ°Ô µÈ´Ù. ÀÌ¿Ü¿¡µµ ´Ù¾çÇÑ È­Çй°Áú¿¡ ÀÇÇؼ­ Á¢Ã˼º ÇǺο°ÀÌ ÀϾ ¼ö ÀÖ´Ù.

    - Á¢Ã˼º ÇǺο°ÀÌ CD4 ¼¼Æ÷(ÁÖ·Î Th1) ¹ÝÀÀÀ̶ó°í ÇÒ ¼ö ÀÖÀ¸¸ç ¾Ç¼ººóÇ÷°ú Á¦ 1Çü ´ç´¢¿Í °°Àº °æ¿ì´Â CD8 ¼¼Æ÷ ¹ÝÀÀÀÌ´Ù. Àν¶¸°À» ºÐºñÇÏ´Â ¼¼Æ÷(pancreatic islet cell)°¡ MHC IÀ» Ç¥ÇöÇÏ°í ÀÌ¿¡ CD8¼¼Æ÷°¡ ¹ÝÀÀÇÏ¿© ¼¼Æ÷ÀÚ¸ê(apoptosis)¸¦ ÀÏÀ¸Å°´Â °ÍÀÌ´Ù. ¾Ç¼º ºóÇ÷ ȯÀÚÀÇ 90%´Â Antiparietal ¼¼Æ÷ Ç×ü¸¦ °¡Áö°í ÀÖ´Ù.

    - T ¼¼Æ÷ ¹ÝÀÀÀÌ ÁÖ·Î ÀϾ±â º¸´Ù´Â º´¸®ÇÐÀûÀ¸·Î À°¾ÆÁ¾(Granuloma)¸¦ Çü¼ºÇÏ´Â Áúº´ÀÌ ÀÖ´Ù. ÀÌ¿¡´Â °áÇÙ, ³ªº´, ±â»ýÃæ °¨¿°, º£¸±·ýÁõ(Berylliosis)¿Í ¼®¸éÁõ(asbestosis) °¡ ÀÖ´Ù. °áÇÙ±Õ, ³ª±Õ ¶Ç´Â ¼®¸é°ú º£¸±·ý°°Àº ¹°ÁúÀ» ´ë½Ä¼¼Æ÷°¡ ó¸® ¶Ç´Â ¼ÒÈ­ÇÏÁö ¸øÇÏ°í T¼¼Æ÷°¡ Áö¼ÓÀûÀ¸·Î µ¿¿øµÇ¾î ÀϾ´Â ¹ÝÀÀÀÌ´Ù. ±×·¯¹Ç·Î Á¦ 4Çü ¹ÝÀÀÀ» ¡®Áö¿¬¹ÝÀÀÇü¡¯°ú ¡®À°¾ÆÁ¾Çü(Granulomatous reaction)¡¯À¸·Î ³ª´©±âµµ ÇÑ´Ù.

    • Áö¿¬¹ÝÀÀÇü : Æ©¹öŬ¸° ¹ÝÀÀ, Á¢Ã˼º ÇǺο°, À̽İźÎ, °©»ó¼±¿°, ¾Ç¼ººóÇ÷, Á¦ 1Çü ´ç´¢
    • À°¾ÆÁ¾Çü : °áÇÙ, ³ªº´, ±â»ýÃæ°¨¿°, º£¸±·ýÁõ, ¼®¸éÁõ

¾Ë·¹¸£±â, °ú¹Î¹ÝÀÀ, ¾Ë·¹¸£°Õ, ¾ÆÅäÇÇ, ¾ÆÅäÇÇÇǺο°ÀÇ Á¤ÀÇ

    ¾Ë·¹¸£±â

      ¾Ë·¹¸£±â´Â ¸é¿ªÇÐÀû ±âÀü¿¡ ÀÇÇØ ¾ß±âµÇ´Â °ú¹Î¹ÝÀÀÀ» ¸»ÇÑ´Ù. ¾Ë·¹¸£±â´Â Ç×ü ¶Ç´Â ¼¼Æ÷¿¡ ÀÇÇؼ­ ¸Å°³µÉ ¼ö ÀÖ´Ù. ´ëºÎºÐÀÇ È¯ÀÚ¿¡¼­ ¾Ë·¹¸£±â ¹ÝÀÀÀ» ÀüÇüÀûÀ¸·Î À¯¹ßÇÏ´Â Ç×ü´Â IgEÇ×ü¿¡ ¼ÓÇϸç, À̵éÀº IgE-¸Å°³¼º ¾Ë·¹¸£±â¿¡ ÀÌȯµÇ¾ú´Ù°í ÇÒ ¼ö ÀÖ´Ù. IgE¿¡ ÀÇÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀº ¡®¾ÆÅäÇÇ È¯ÀÚ¡¯¿¡¼­¸¸ ÀϾ´Â °ÍÀº ¾Æ´Ï´Ù. ºñ IgE-¸Å°³¼º ¾Ë·¹¸£±â´Â dextran-¸é¿ªº¹ÇÕü¿¡ ÀÇÇÑ ¾Æ³ªÇʶô½Ã½º³ª, ¿äÁòÀº µå¹°Áö¸¸ °ú°Å¿¡ Á¦IIIÇü °ú¹Î¹ÝÀÀÀ¸·Î ºÐ·ùµÇ¾ú´ø Ç÷ûº´ÀÇ ¿¹¿¡¼­¿Í °°ÀÌ IgGÇ×ü¿¡ ÀÇÇØ ¸Å°³µÉ ¼ö ÀÖ´Ù. ¾Ë·¹¸£±â¼º ±â°üÁöÆó ¾Æ½ºÆ丣±æ·ç½ºÁõ(ABPA)¿¡¼­´Â IgE¿Í IgGÇ×ü°¡ ¸ðµÎ ¹ß°ßµÈ´Ù. ¾Ë·¹¸£±â¼º Á¢ÃËÇǺο°Àº ¸²ÇÁ±¸¿¡ ÀÇÇØ ¸Å°³µÇ´Â ´ëÇ¥ÀûÀÎ ¾Ë·¹¸£±â ÁúȯÀÌ´Ù(À¯·´ÇÐȸ Á¤ÀÇ).

      ¾Ë·¹¸£±â ¹ÝÀÀÀ̶õ ¾Ë·¹¸£°Õ(¾Ë·¹¸£±âÇ׿ø)°ú °°Àº ºñÀÚ±â(non-self) ¹°Áú¿¡ ´ëÇÑ º´ÀûÀÎ °ú¹Î¹ÝÀÀÀ̶ó°í ÇÒ ¼ö ÀÖ´Ù. ÀÌ´Â Th2 ¼¼Æ÷¹ÝÀÀÀ¸·Î ´ëÇ¥µÇ´Âµ¥ ÀÌ¿¡´Â IL-4, IL-5¿Í IL-13°ú °°Àº »çÀÌÅäÄ«ÀÎÀÌ °ü¿©ÇÏ°í RANTES, eotaxin°ú MCP-3¿Í °°Àº ÄɸðÄ«ÀÎÀÌ ¾Ë·¹¸£±â ¿°Áõ¹ÝÀÀ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. ÀÚ±â(self)¹°Áú¿¡ ´ëÇؼ­ º´ÀûÀÎ °ú¹Î¹ÝÀÀÀ» º¸À̸é À̸¦ ÀÚ°¡¸é¿ªÁúȯÀÌ¶ó ¸»ÇÏ°Ô µÈ´Ù.

    ¾Ë·¹¸£°Õ

      ¾Ë·¹¸£°ÕÀº ¾Ë·¹¸£±â¸¦ ÀÏÀ¸Å°´Â Ç׿øÀÌ´Ù. IgE³ª IgGÇ×ü¿Í ¹ÝÀÀÇÏ´Â ´ëºÎºÐÀÇ ¾Ë·¹¸£°ÕÀº ´Ü¹éÁú Ç׿øÀ¸·Î, º¸Åë ź¼öÈ­¹°±â¸¦ °®°í ÀÖ´Ù. ±×·¯³ª ¶§·Î´Â ¼ø¼öÇÑ Åº¼öÈ­¹°µµ ¾Ë·¹¸£°ÕÀÌ µÉ ¼ö ÀÖ´Ù°í ÃßÃøµÈ´Ù. µå¹°°Ô´Â ÇÕÅÙÀ¸·Î ÀÛ¿ëÇÏ´Â isocyanate³ª anhydride °°Àº ÀúºÐÀÚ È­Çй°µµ IgEÇ×ü¿Í ¹ÝÀÀÇÏ´Â ¾Ë·¹¸£°ÕÀ¸·Î ºÒ¸°´Ù. ¾Ë·¹¸£±â¼º Á¢ÃË ÇǺο°¿¡¼­´Â T¼¼Æ÷¿Í ¹ÝÀÀÇÏ´Â Å©·Ò, ´ÏÄÌ, formaldehyde °°Àº ÀúºÐÀÚ ¹°ÁúÀÌ ÁÖ¿ä ¾Ë·¹¸£°ÕÀÌ´Ù.(À¯·´ÇÐȸ Á¤ÀÇ)

      ¾Ë·¹¸£°Õ(Allergen)À̶õ IgE¹ÝÀÀÀ» ÁõÆøÇÏ¿© Áõ»óÀ» ÀÏÀ¸Å°´Â ¹°ÁúÀÌ´Ù. ±×·¯³ª ÀÌ´Â IgE ¹ÝÀÀ ¾øÀ̵µ ÀϾ±âµµ Çϴµ¥, ¿¹¸¦µé¾î IgE ¹ÝÀÀ°ú ¿¬°ü¼ºÀÌ ÀûÀº ¼ÒÈ­±â°è ¾Ë·¹¸£±â ¹ÝÀÀÀº T¼¼Æ÷°¡ °ü¿©ÇÏ´Â ¸é¿ªÇÐÀû °ú¹Î¹ÝÀÀÀÌ°í ¾Ë·¹¸£±â Áõ»óÀ» À¯¹ßÇÏ´Â ¾Ë·¹¸£°ÕÀÌÁö¸¸ IgE¸¦ ¸Å°³ÇÏÁö ¾Ê´Â´Ù. À̸¦ ÈçÈ÷ ¡®³»Àμº¡¯ À̶ó°í Ç¥ÇöÇϱ⵵ ÇÑ´Ù. ¾Ë·¹¸£°ÕÀ̶õ ¿ë¾î´Â Á¾Á¾ Ç׿ø(Antigen)°ú °°Àº ¶æÀ¸·Î »ç¿ëµÇ±âµµ ÇÏÁö¸¸ Ç׿øÀÌ ¾Ë·¹¸£°ÕÀº ¾Æ´Ï´Ù. ¿¹¸¦ µé¾î Áý¸ÕÁö Áøµå±â´Â ¾Ë·¹¸£°ÕÀ̶ó°í ÇÏÁö¸¸ Ç׿øÀ̶ó´Â Ç¥ÇöÀº Àß ¾²Áö ¾Ê´Â´Ù. ¿ªÀ¸·Î ¾î¶² ±ÕÀÌ Ã¼³»¿¡ µé¾î¿ÔÀ» ¶§ À̸¦ Ç׿øÀ̶ó°í Ç¥ÇöÇÏÁö ¾Ë·¹¸£°ÕÀ̶ó°í Ç¥ÇöÇÏÁö´Â ¾Ê´Â´Ù.

    ¾ÆÅäÇÇ

      ¾ÆÅäÇÇ´Â º¸Åë ¼Ò¾Æ±â ¶Ç´Â »çÃá±â¿¡ ¾Ë·¹¸£°Õ¿¡ °¨À۵Ǿî IgE Ç×ü¸¦ »ý»êÇÏ´Â °³ÀÎÀû ȤÀº °¡Á·Àû ¼ºÇâÀÌ´Ù. ±× °á°ú õ½Ä, ºñ/°á¸·¿° ¶Ç´Â ½ÀÁø µî ÀüÇüÀû Áõ»óÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. ¡®¾ÆÅäÇÇ¡¯³ª ¡®¾ÆÅäÇǼº¡¯À̶ó´Â ¿ë¾î´Â ´©±¸³ª ³ëÃâµÇ´Â ÁÖº¯È¯°æÀÇ ¾Ë·¹¸£°Õ¿¡ ´ëÇØ ´ë´Ù¼öÀÇ »ç¶÷µéÀÌ Áö¼ÓÀûÀÎ IgEÇ×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°Áö ¾Ê´Â °Í°ú´Â ´Þ¸® IgE-°¨ÀÛÀ» ÀÏÀ¸Å°´Â À¯ÀüÀû ¼ÒÁúÀ» ±â¼úÇÏ´Â µ¥¿¡ ±¹ÇÑÇؼ­ »ç¿ëÇØ¾ß ÇÑ´Ù. Áï ¾ÆÅäÇǶõ IgE Ç×ü °í ¹ÝÀÀÀÚ¿¡ ´ëÇÑ ÀÓ»óÀû Á¤ÀǶó ÇÒ ¼ö ÀÖ´Ù. ¾ÆÅäÇǶõ ¿ë¾î´Â Ç÷û IgEÇ×ü³ª ¾ç¼º ÇǺδÜÀÚ½ÃÇèÀ¸·Î IgE °¨ÀÛÀÌ Áõ¸íµÇ±â Àü¿¡´Â »ç¿ëÇؼ­´Â ¾ÈµÈ´Ù. ÀüÇüÀûÀÎ ¾ÆÅäÇÇȯÀÚ¿¡¼­ ³ªÅ¸³ª´Â ¾Ë·¹¸£±â Áõ»ó¿¡´Â, ¿¹¸¦ µé¾î ¡®¾ÆÅäÇǼº õ½Ä¡¯ °°ÀÌ ¾ÆÅäÇǼºÀ̶õ ¿ë¾î¸¦ ¾µ ¼ö ÀÖÀ» °ÍÀÌ´Ù. ±×·¯³ª ÀϹÝÀûÀ¸·Î´Â IgE-¸Å°³¼º õ½ÄÀ» ¾ÆÅäÇǼº õ½ÄÀ̶ó°íÇؼ­´Â ¾ÈµÈ´Ù. ¶ÇÇÑ ¸·½Ã·ù °ïÃæÀÇ µ¶À̳ª ¾à¹°Ã³·³ ÈçÄ¡ ¾ÊÀº ¾Ë·¹¸£°ÕÀÇ ´ë·® ³ëÃâ¿¡ÀÇÇÑ ÇǺδÜÀÚ½ÃÇè ¾ç¼º¹ÝÀÀÀ̳ª IgEÇ×üÀÇ Á¸À縦 °¡Áö°í ¾ÆÅäÇǶó°í Áø´ÜÇؼ­´Â ¾ÈµÈ´Ù.(À¯·´ÇÐȸ Á¤ÀÇ)

      ¾ÆÅäÇǶõ Á¼Àº Àǹ̷δ IgE°¡ Áõ°¡µÇ¾î ÀÖ´Â »óŸ¦ ¸»ÇÑ´Ù. IgE°¡ ±â»ýÃæÀ̳ª ´Ù¸¥ º´À¸·Îµµ Áõ°¡µÉ ¼ö´Â ÀÖÁö¸¸ ¾ÆÅäÇÇ´Â À¯ÀüÀûÀÎ °æÇâÀ» ¶ì°Ô µÈ´Ù. ¾Ë·¹¸£±â´Â À̺¸´Ù ³ÐÀº Àǹ̷Π»ç¿ëµÈ´Ù.

    °ú¹ÎÁõ

      °ú¹ÎÁõ(hypersensitivity)Àº Á¤»óÀο¡¼­´Â °ü¿ëµÇ´Â ¾î¶² ƯÁ¤ÇÑ Àڱؿ¡ ³ëÃâµÊÀ¸·Î½á °´°üÀûÀ¸·Î ÀçÇö °¡´ÉÇÑ Áõ»ó ¶Ç´Â ÁõÈÄ°¡ À¯¹ßµÇ´Â °ÍÀÌ´Ù. ºñ ¾Ë·¹¸£±â¼º °ú¹ÎÁõ : ÀÌ´Â ¸é¿ªÇÐÀû ±âÀüÀÌ Áõ¸íµÇÁö ¾ÊÀº °ú¹ÎÁõÀ» ±â¼úÇϱâ À§ÇÑ ¿ë¾îÀÌ´Ù.(À¯·´ÇÐȸ Á¤ÀÇ)

      °ú¹Î¹ÝÀÀÀ̶õ ¾Ë·¹¸£±âº¸´Ù ´õ ³ÐÀº ¹üÀ§·Î »ç¿ëÇÑ´Ù. ÀÌ´Â ¸é¿ªÇÐÀû ±âÀü¿¡ ÀÇÇÏÁö ¾Ê°íµµ ÀϾ ¼ö ÀÖ´Â ¿©·¯ ÁõÆøµÈ Áõ»ó, ¹ÝÀÀÀ» ¸»ÇÑ´Ù.

    Áúȯ¿¡ °üÇÑ ¿ë¾î

    õ½Ä(GINA Á¤ÀÇ¿¡ ÀÇÇÔ)

      õ½ÄÀº °¢Á¾ ¼¼Æ÷, ƯÈ÷ ºñ¸¸¼¼Æ÷, È£»ê±¸, T ¸²ÇÁ±¸°¡ ÀÛ¿ëÇÏ´Â ±âµµÀÇ ¸¸¼º ¿°Áõ¼º ÁúȯÀÌ´Ù. Áúº´°¨¼ö¼ºÀÌ ÀÖ´Â »ç¶÷¿¡¼­ ÀÌ·¯ÇÑ ±âµµ ¿°ÁõÀº ƯÈ÷ ¹ã°ú »õº®¿¡ õ¸í, ¼ûÂü, °¡½¿ ´ä´äÇÔ, ±âħ µîÀÇ Áõ»óÀ» ¹Ýº¹ÀûÀ¸·Î ÀÏÀ¸Å²´Ù. À̵é Áõ»óÀº ÈçÈ÷ ¿©·¯ Á¤µµÀÇ Àü¹ÝÀû ±â·ùÀå¾Ö¸¦ ¼ö¹ÝÇϴµ¥ ÀÌ´Â ÀúÀý·Î ȤÀº Ä¡·á¿¡ ÀÇÇؼ­ Àû¾îµµ ÀϺκРȸº¹µÉ ¼ö ÀÖ´Ù. ±âµµ ¿°ÁõÀº ¶ÇÇÑ °¢Á¾ Àڱؿ¡ ´ëÇÑ ±âµµ¹ÝÀÀ¼ºÀÇ Áõ°¡Çö»óÀ» ÀÏÀ¸Å²´Ù.

      ¾Ë·¹¸£±â¼º õ½ÄÀº ¸é¿ªÇÐÀû ±âÀü¿¡ ÀÇÇÑ Ãµ½ÄÀ¸·Î, IgE-¸Å°³¼º ±âÀüÀÇ Áõ°Å°¡ ÀÖÀ¸¸é IgE-¸Å°³¼º õ½ÄÀ¸·Î ºÎ¸¥´Ù. IgEÇ×ü´Â Á¶±â(Áï¹ß¼º)¿Í Èıâ õ½Ä¹ÝÀÀÀ» ¸ðµÎ ¾ß±âÇÒ ¼ö ÀÖ´Ù. ±×·¯³ª ´Ù¸¥ ¾Ë·¹¸£±â Áúȯ¿¡¼­¿Í °°ÀÌ ÈÄ±â ¹× Áö¹ß¼º ¹ÝÀÀ¿¡´Â T¼¼Æ÷ÀÇ °ü¿©°¡ Áß¿äÇÏ´Ù°í ¿©°ÜÁø´Ù. Áõ»óÀÇ Áö¼Ó±â°£¿¡ µû¶ó õ½ÄÀº °£Ç漺 ȤÀº Áö¼Ó¼ºÀ¸·Î ºÒ¸± ¼ö ÀÖ´Ù.(À¯·´ÇÐȸ Á¤ÀÇ)

    ºñ ¾Ë·¹¸£±â¼º õ½Ä

      ÀÌ´Â ºñ ¸é¿ªÇÐÀû ÇüÅÂÀÇ Ãµ½ÄÀ» À§ÇÑ ¿ë¾î´Ù. ¿ÜÀμº, ³»Àμº°ú °°Àº °ú°ÅÀÇ ¿ë¾îµéÀº ¾Ë·¹¸£±â¼º°ú ºñ ¾Ë·¹¸£±â¼º õ½ÄÀ» ±¸ºÐÇÏ´Â µ¥¿¡ ´õ ÀÌ»ó »ç¿ëÇÏÁö ¾Ê´Â °ÍÀÌ ÁÁ´Ù.(À¯·´ÇÐȸ Á¤ÀÇ)

    ºñ°á¸·¿°

      ÄÚ¿Í °á¸·¿¡ ÀϾ´Â ¸é¿ªÇÐÀû °ú¹Î¹ÝÀÀÀÇ Áõ»óÀ» ¾Ë·¹¸£±â¼º ºñ°á¸·¿°À̶ó°í Çϸç, ´ëºÎºÐ IgE-¸Å°³¼ºÀÌ´Ù. Áõ»óÀÇ Áö¼Ó±â°£¿¡ µû¶ó °£Ç漺°ú Áö¼Ó¼ºÀ¸·Î ±¸ºÐÇÏ´Â °ÍÀÌ À¯¿ëÇÒ ¼ö ÀÖ´Ù.(À¯·´ÇÐȸ Á¤ÀÇ)

    ÇǺο°

      ÇǺο°Àº ÇǺÎÀÇ ±¹¼ÒÀû ¿°Áõ¿¡ ´ëÇÑ Æ÷°ýÀû ¿ë¾îÀÌ´Ù. ÈçÈ÷ ¡°¾ÆÅäÇÇ ½ÀÁø/ÇǺο°¡±À¸·Î ¾Ë·ÁÁø ÁúȯÀº ´ÜÀÏ ÁúȯÀÌ ¾Æ´Ï¸ç °øÅëµÈ Ư¡À» °®´Â ¿©·¯ ÁúȯÀÇ ÁýÇÕÀ̶ó ÇÒ ¼ö ÀÖ´Ù. ÇǺο°º¸´Ù ´õ ÀûÀýÇÑ ¿ë¾î´Â ½ÀÁøÀÌ´Ù. ¾Ë·¹¸£±â¼º õ½Ä, ºñ/°á¸·¿°°ú ¿¬°èµÈ, Áï ¾ÆÅäÇÇ Ã¼ÁúÀÚÀÇ ½ÀÁøÀº ¾ÆÅäÇǼº ½ÀÁøÀ̶ó ºÒ·¯¾ß ÇÑ´Ù. ÀúºÐÀÚ·®ÀÇ È­Çй°Áú¿¡ Á¢ÃËÇϸé ÁÖ·Î TH1¸²ÇÁ±¸¿¡ ÀÇÇØ ¸Å°³µÇ´Â ¾Ë·¹¸£±â¼º Á¢ÃË ÇǺο°ÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.(À¯·´ÇÐȸ Á¤ÀÇ)

      ºñ ¾Ë·¹¸£±â¼º ÇǺο°Àº Àڱؼº/µ¶¼º Á¢ÃË ÇǺο°À¸·Îµµ ºÒ¸± ¼ö ÀÖ´Ù.

IgE´Â ¾Ë·¹¸£±â ÁúȯÀ» ÀÌÇØÇÏ´Â ÇÙ½ÉÇ×üÀ̸ç 1960³â´ë ¾Ë·ÁÁ³´Ù.

    - ¾Ë·¹¸£±â ÁúȯÀº ÀÌ¹Ì 100¿©³â Àü¿¡ ¾Ë·ÁÁ³´Ù. ±× ´ç½Ã ¾Ë·¹¸£±â ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷ÀÇ Ç÷ûÀ» °Ç°­ÇÑ »ç¶÷¿¡°Ô (ÇǺΠ¾ÈÂÊ¿¡) Åõ¿©ÇÏ¿´À» ¶§ ¾Ë·¹¸£±â¸¦ ÀÏÀ¸Å°´Â ¹«¾ùÀΰ¡°¡ Á¤»óÀο¡°Ô ³Ñ¾î°¡¼­ ¾Ë·¹¸£±â¸¦ ÀÏÀ¸Å²´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ¾úÁö¸¸ ±×°ÍÀÌ ¹«¾ùÀÎÁö¸¦ Àß ¾ËÁö ¸øÇÏ¿´´Ù. À̸¦ reagin À̶ó°í ÇÏ¿´´Ù. ÀÌÈÄ ÀÌ ¹°ÁúÀÌ ÀϺ»ÀÎ ¿¬±¸ÀÚ¿¡ ÀÇÇØ 1960³â´ë IgE ¶ó´Â °ÍÀÌ È®ÀεǾú°í ¾Ë·¹¸£±â ¸é¿ª ±âÀü¿¡ ´ëÇÑ ¼³¸íÀÌ Á¡Â÷ ºÐ¸íÇØÁö±â ½ÃÀÛÇÏ¿´´Ù.

    - IgE´Â Ç×üÀÌ´Ù. Ç×ü¶õ ¿ÜºÎ¹°Áú Àڱؿ¡ ´ëÇØ ¹ÝÀÀÇÏ´Â ¹°ÁúÀÌ´Ù. ÀÌ¿¡´Â IgE ÀÌ¿Ü¿¡µµ IgG, IgM, IgD ¿Í IgA°¡ ÀÖ´Ù. ÀÌ·¯ÇÑ Ç×ü°¡ ¸¸µé¾îÁ® ½Åü °÷°÷À» µ¹¸é¼­ °¨½Ãü°è¸¦ ÀÌ·é´Ù.

    ±×¸²) ¸é¿ª±Û·ÎºÒ¸°ÀÌ´Ù. Ç×ü´Â ´ëºÎºÐ ºñ½ÁÇÑ ±¸Á¶½ÄÀ» °¡Áö°í ÀÖ´Ù. µÎ°³ÀÇ µ¿ÀÏÇÑ Áß¼â(Heavy chain)¿Í °æ¼â(Light chain)·Î ±¸¼ºµÇ¾î ÀÖ°í °¢°¢Àº ¸ðµÎ °¡º¯ºÎÀ§(Variable region)¿Í ÀÏÁ¤ºÎÀ§(Constant region)¸¦ °¡Áö°í ÀÖ´Ù. µÎ °³ÀÇ °¡º¯ ºÎÀ§°¡ ¼­·Î ÇÕÃÄÁö¸é¼­ Ç׿ø°áÇÕ ºÎÀ§¸¦ Çü¼ºÇÑ´Ù.

IgE¸¦ ¸¸µå´Â ¼¼Æ÷´Â B¼¼Æ÷(ÇüÁú¼¼Æ÷)ÀÌ´Ù.

    - IgE´Â Á¦ 1Çü ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ÁÖ¿äÇÑ ¸é¿ª±Û·ÎºÒ¸°ÀÌ´Ù. ÀÌ·¯ÇÑ ¸é¿ª±Û·ÎºÒ¸°À» ¸¸µå´Â °ÍÀº B ¼¼Æ÷ÀÌ´Ù. ÇÑ°¡Áö B ¼¼Æ÷´Â ÇÑ°¡Áö Ç×ü¸¸ ¸¸µé¾î ³¾ ¼ö ÀÖ´Ù.(Clonal selection hypothesis). B ¼¼Æ÷ÀÇ MHC II ¿Í TCR, °øµ¿ÀÚ±ØÀÎÀÚÀÎ CD40°ú IL-4, IL-5¿Í IL-6 °°Àº »çÀÌÅäÄ«ÀÎ ¿µÇâÀ¸·Î ºÐ¿­(Proliferation)°ú ºÐÈ­(differentiation; Class switch, Affinity maturation) ÇÑ´Ù. Class switch´Â IgM¿¡¼­ IgG, IgA¿Í IgE·Î º¯ÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. IL-4 ´Â IgM¿¡¼­ IgE º¯È¯À» À¯µµÇϸç ÀÎÅÍÆä·Ð °¨¸¶(IFN-gamma) ´Â ¾ïÁ¦ÇÑ´Ù. ÀÌ¿Ü¿¡µµ IgE¸¦ »ý¼º°ú Á¶ÀýÇÏ´Â ¸ÞÄ«´ÏÁò¿¡´Â ¿©·¯ÀÎÀÚ°¡ °ü¿©¸¦ ÇÑ´Ù.

    - ÀÌÁß T ¼¼Æ÷¿Í »çÀÌÅäÄ«ÀÎÀº ¸Å¿ì Áß¿äÇÏ´Ù. ¾Ë·¹¸£°ÕÀÌ B¼¼Æ÷ÀÇ Æ¯ÀÌ IgM°ú °áÇÕÇÏ¸é ¼¼Æ÷³»¿¡¼­ 󸮵Ǿî MHC class II¸¦ ÅëÇØ T¼¼Æ÷Á¦½ÃµÇ°í CD40/CD40L °áÇÕÀÌ À¯µµµÇ°í ´Ù¸¥ º¸Á¶ ºÐÀÚµé ¶ÇÇÑ È°¼ºÈ­µÇ¾î »óÈ£ÀÛ¿ëÀÌ ÀϾ´Ù. ÀÌ·ÎÀÎÇØ IL-4°¡ T¼¼Æ÷¿¡¼­ ºÐºñµÇ¸ç B¼¼Æ÷´Â IL-4¿¡ ÀÇÇØ IgE isotype switchingÀÌ À¯µµµÇ¾î IgE°¡ »ý¼ºµÈ´Ù. ÀÌ´Â IL-5, IL6 ¿¡ ÀÇÇؼ­ Áõ°­µÈ´Ù.

    - À¯ÀüÀûÀÎ ¿äÀο¡ ÀÇÇؼ­ IgE »ý¼ºÀÌ Áõ°¡µÇ±âµµ ÇÑ´Ù. ÀÌ¿¡´Â 5q31-33, 11q13°ú 6p µîÀÌ ÀÖ´Ù.

    - ÀÌ·¸°Ô ºÐºñµÈ IgE´Â È£»ê±¸, ´Ü±¸(monocyte), ´ë½Ä¼¼Æ÷, Ç÷¼ÒÆÇ°ú È£¿°±â±¸, ºñ¸¸¼¼Æ÷ÀÇ Fc ¼ö¿ëü¿Í °áÇÕÇÑ´Ù. IgE°¡ °áÇÕÇÏ´Â ¼ö¿ëü´Â Å©°Ô µÎ°¡Áö·Î ³ª´¶´Ù. FceRI(¿¡ÇÁ¾¾ÀԽǷи®¼ÁÅÍ¿ø)°ú FceRIIÀÌ´Ù. FceRIÀº IgE¿Í °­·ÂÇÑ Ä£È­·Â(high-affinity)°¡ ÀÖ°í »ó´ëÀûÀ¸·Î FceRII´Â low-affinity¶ó ºÒ¸°´Ù. FceRII´Â CD23 À̶ó°í ÇÑ´Ù. CD23Àº B ¼¼Æ÷¿¡ ¹ßÇöµÇ¸ç Ç׿øÁ¦½Ã ±â´ÉÀ» ¿øÈ°ÇÏ°Ô ÇÒ»Ó¸¸¾Æ´Ï¶ó B¼¼Æ÷¿¡¼­ ´Ù¾çÇÑ È°µ¿À» ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. IgE°¡ ÀÌ·¯ÇÑ ¼ö¿ëü¿Í °áÇÕÇÏ°Ô µÈ »óÅ¿¡¼­ ¾Ë·¹¸£°ÕÀÌ µé¾î¿ÔÀ» ¶§ ¾Ë·¹¸£°ÕÀº IgE¿Í °áÇÕÇÏ¿© ´Ù¾çÇÑ ¹ÝÀÀÀ» ÀÏÀ¸Å²´Ù.

    - IgE´Â Ç÷Áß¿¡ ¸Å¿ì ³·Àº ³óµµ·Î Á¸ÀçÇÑ´Ù. ¿¹¸¦µé¾î IgGº¸´Ù ¹é¸¸ºÐÀÇ 1Á¤µµ ³óµµÀÌ´Ù. ¾ÆÅäÇÇ°¡ ¾Æ´Ñ »ç¶÷ÀÇ Ç÷Áß¿¡´Â 1 ~ 400 ng/mL Á¤µµ ÀÖ´Ù. ÀÌ·¸°Ô ³·Àº ³óµµ·Î Á¸ÀçÇÏ¿© ¸é¿ª±Û·ÎºÒ¸° Áß °¡Àå ´Ê°Ô ¹ß°ßµÇ¾ú´Ù. ±×·¯³ª ±â»ýÃæ °¨¿°ÀÌ ÀϾ°Å³ª Wiskott-Aldrich ÁõÈıº, Hyper IgE ÁõÈıºÀ» ¾Î´Â »ç¶÷Àº 5 – 100 ug/mL ÀÇ °í³óµµ°¡ º¸À̱⵵ ÇÑ´Ù. ¶ÇÇÑ IgGÀÇ ¹Ý°¨±â°¡ 21 ÀÏ ÀÌÁö¸¸ IgE´Â 2.5 ÀÏ¿¡ ºÒ°úÇÏ´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í IgE´Â ü³»¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. ÀÌ·¯ÇÑ IgE¸¦ °áÁ¤ÇÏ´Â °¡Àå Áß¿äÇÑ »çÀÌÅäÄ«ÀÎÀº IL-4 ¿Í IL-13 ÀÌ´Ù.

    - IgEÀÇ Ç× IgE´Â ÁßÁõ õ½ÄÄ¡·áÁ¦·Î °³¹ßµÇ¾ú°í À̸¦ Omalizumab À̶ó°í ÇÑ´Ù. ¾ÆÁ÷ ±¹³»¿¡ µé¾î¿Í ÀÖÁö¾ÊÁö¸¸ °ð ½ÃÆÇµÉ ¿¹Á¤ÀÌ´Ù.

¾Ë·¹¸£°ÕÀº ¾Ë·¹¸£±â ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ¹°ÁúÀÌ´Ù.

    - ¾Ë·¹¸£°ÕÀ̶õ ¾Ë·¹¸£±â ¸é¿ª¹ÝÀÀ(IgE ; Allergenic)À» À¯µµÇÏ´Â ¹°ÁúÀ» ¸»ÇÑ´Ù. ÀÌ´Â Ç׿ø(IgG ; Antigenic)°ú ´Ù¸¥ Àǹ̷Π»ç¿ëÇÑ´Ù.

    - ¾Ë·¹¸£°ÕÀº ´Ü¹éÁúÀ̾î¾ß ÇÑ´Ù. ź¼öÈ­¹° ¶ÇÇÑ ¾Ë·¹¸£°ÕÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖÀ» °ÍÀÌ¶ó ¿©°ÜÁöÁö¸¸ ÀüÅëÀûÀ¸·Î ¾Ë·¹¸£°ÕÀº ´Ü¹éÁúÀÌ´Ù. Åë»óÀûÀ¸·Î ¾Ë·¹¸£°ÕÀ̶óÇÔÀº IgE ¹ÝÀÀ ¸Å°³ÀÛ¿ëÀÌ ÀϾ¾ß ÇÑ´Ù. Áï ƯÀÌ IgE°¡ ¹ß°ßµÇ¾î¾ß ÇÑ´Ù. ºñ¸¸¼¼Æ÷ ¶Ç´Â È£¿°±â±¸¿¡ IgE °¡ FceRI Cross-linkingÀÌ ÀϾ¾ß ¼¼Æ÷³» ½ÅÈ£Àü´ÞÀÌ ÀϾ´Âµ¥ À̸¦ À§Çؼ­´Â ¾Ë·¹¸£°ÕÀº Àû¾îµµ µÎ°³ÀÇ IgE °áÇÕºÎÀ§(epitope)¸¦ °¡Áö°í ÀÖ¾î¾ß ÇÑ´Ù. À̸¦ À§Çؼ­´Â °¢°¢ ÃÖ¼ÒÇÑ 15 AA(amino acid) ±æÀ̸¦ °¡Áö°í ÀÖ¾î¾ß ÇÑ´Ù. Áï ¾Ë·¹¸£°ÕÀº ÃÖ¼ÒÇÑ 30 AA Àܱâ (ºÐÀÚ·® 3 kD) ÀÌ»óÀÇ Å©±â¸¦ °¡Áö°í ÀÖ¾î¾ß ÇÑ´Ù. º¸ÅëÀº 5 K ~ 50 KD ³»¿ÜÀÌ´Ù. ¸¸ÀÏ À̺¸´Ù ÀûÀº Å©±âÀÇ ¹°ÁúÀÌ ¾Ë·¹¸£°ÕÀ¸·Î ÀÛ¿ëÇϱâ À§Çؼ­´Â Carrier ´Ü¹éÁú°ú Hapten°úÁ¤À» ÅëÇؼ­ ¾Ë·¹¸£°Õ ¿ªÇÒÀ» ÇÑ´Ù.

    - ¸¹Àº ´Ü¹éÁúÀº ´çÈ­(glycosylation)°úÁ¤À» ¹â¾Æ ´ç´Ü¹éÁú(Glycoprotein) ÇüŸ¦ ¶í´Ù. ¾Ë·¹¸£°Õ¶ÇÇÑ ´ç´Ü¹éÁúÀ» ¶ì´Â °æ¿ì°¡ ¸¹´Ù. ´Ü¹éÁú °íÀ¯ÇÑ ¼ºÁú°ú ´ç´Ü¹éÁúÀÇ ¾Ë·¹¸£°Õ ¼ºÁú(IgE, Allergenic)°ú ¸é¿ªÇÐÀû ¼ºÁú(IgG, Immunogenic)¿¡ ´ëÇؼ­´Â Àß ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù. ´ç´Ü¹éÁúÀº ´Ü¹éÁú ÀÚüº¸´Ù APC Èí¼ö°¡ ¸î¹è ´õ ¸¹ÀÌ ÀϾ°í ÀÌ´Â APCÀÇ ¼ö¿ëüÀÇ ÇϳªÀÎ MMRÀÌ ´çÀ» ½±°Ô Èí¼öÇÏ´Â ¼ºÁú¿¡ ±âÀÎÇÑ´Ù. ÀÌ·ÎÀÎÇØ ´ç´Ü¹éÁúÀº º¸´Ù ¸¹ÀÌ APC¿¡¼­ ó¸®µÇ¸ç ¼­·Î ´Ù¸¥ °æ·Î¸¦ ÅëÇØ Ã³¸®µÈ´Ù.

    - ÀÌ·¯ÇÑ Æ¯ÀÌ IgE¸¦ ¸¸µå´Â ÀÛ¾÷Àº T ¼¼Æ÷¿¡¼­ºÎÅÍ ½ÃÀÛÇÑ´Ù. T ¼¼Æ÷´Â ´Ü¹éÁú ÀÚü¸¦ ÀνÄÇÏÁö ¸øÇÑ´Ù. ÀÌ´Â APC¸¦ ÅëÇÏ¸ç ¾î¶² ´Ü¹éÁúÀº Th2 ¹ÝÀÀÀÌ À¯µµµÇ°í ¾î¶² ´Ü¹éÁúÀº ¹«¹ÝÀÀÀÌ ÀϾ´ÂÁö¿¡ ´ëÇؼ­´Â Àß ¾Ë·ÁÁöÁö ¾Ê¾Ò´Ù.

    - IgE¿Í °áÇÕÇÒ ¼ö ÀÖ´Â °ÍµéÀ» ¾Ë·¹¸£°ÕÀ̶ó°í ÇÑ´Ù¸é ¾Ë·¹¸£°Õ¿¡´Â ¿©·¯ ¹°ÁúµéÀÌ ÀÖ´Ù. ÈçÈ÷ À̸¦ ÈíÀÔ¼º ¾Ë·¹¸£°Õ°ú ½ÄÇ° ¾Ë·¹¸£°ÕÀ¸·Î ³ª´©°í ÈíÀÔ¼º ¾Ë·¹¸£°ÕÀº ¶Ç´Ù½Ã ½Ç³» ¾Ë·¹¸£°Õ(Áý¸ÕÁö Áøµå±â, °í¾çÀÌ, ½Ç³» °õÆÎÀÌ, °­¾ÆÁö)°ú ½Ç¿Ü ¾Ë·¹¸£°Õ(½Ç¿Ü °õÆÎÀÌ, ²É°¡·ç)·Î ³ª´«´Ù.

    - ¾Ë·¹¸£°Õ ¸í¸í¹ýÀº 3 ´ÜÀ§·Î ÀÌ·ç¾î Áö¾ú´Ù. ÀÌ´Â 1986³â WHO/IUIS(International Union o Immunological Societies. www.allergen.org)¿¡¼­ ü°èÈ­ÇÏ¿© 1994³â °³Á¤µÈ °ÍÀ» »ç¿ëÇÏ°í ÀÖ´Ù. ¿¹¸¦µé¾î Áý¸ÕÁö Áøµå±â(House Dust midt)¸¦ " Der p 1"(´õ-ÇÇ¿ø)À̶ó°í ºÎ¸£´Âµ¥ ÀÌ´Â Áý¸ÕÁö Áøµå±âÀÇ ÇÑ ¾Ë·¹¸£°ÕÀ» À̸¥ °ÍÀÌ´Ù. À̶§ ù±ÛÀÚÀÎ 'Der'´Â Áý¸ÕÁö Áøµå±âÀÇ ¼Ó(áÕ, genus)ÀÇ À̸§ÀÎ 'Dermatophagoides'ÀÇ ¾Õ ¼¼±ÛÀÚ¸¦ µý °ÍÀÌ°í µÎ¹ø°ÀÎ 'p'´Â Á¾(ðú, species)ÀÎ 'pteronyssinus'ÀÇ ¾Õ±ÛÀÚ¸¸ µû¿Â °ÍÀÌ°í '1'Àº ¹ß°ßÇÑ ¼ø¼­ÀÌ´Ù. ±×·¯¹Ç·Î 'Der p 2'´Â Dermatophagoides pteronyssinus µÎ¹ø° ¹ß°ßÇÑ ¾Ë·¹¸£°ÕÀ̶ó°í »ý°¢ÇÏ¸é µÈ´Ù. ÀÌ¿Ü¿¡µµ ¸¹ÀÌ »ç¿ëµÇ´Â ¾Ë·¹¸£°Õ À̸§Àº ´ÙÀ½°ú °°´Ù.(±âÀÔ¹æ¹ýÀº ´Ü¾î¸¦ ÀÌŸ¯Ã¼·Î ÇÏÁö ¸»°í °¢°¢¿¡ ÇÑÄ­¶ç¿ö¼­ ¾´´Ù)

    - Á¶Ç׿ø ; »ý¹°Ã¼ Àüü¿¡¼­ ÃßÃâÇÑ Ç׿ø

    - ÁÖ ¾Ë·¹¸£°Õ(Major allergen) ; ¸ðµç ¹àÇôÁö´Â ¾Ë·¹¸£°ÕÀÌ ±â·ÏµÇ´Â °ÍÀº ¾Æ´Ï´Ù. Áý¸ÕÁö Áøµå±â´Â 50¿© Ç׿øÀÌ ¹àÇôÁ³°í ÀÌÁß 30¿©°¡Áö°¡ ¾Ë·¹¸£°ÕÀ¸·Î ÀÛ¿ëÇÑ´Ù. ÀÌ·¯ÇÑ ¾Ë·¹¸£°Õ Áß ÁÖ¿ä ¾Ë·¹¸£°ÕÀ̶õ Á¶Ç׿ø¿¡¼­ ÃßÃâÇÑ Ç׿ø Áß ±× ¹°Áú¿¡ ¾Ë·¹¸£±â ¹ÝÀÀÀÌ Àִ ȯÀÚÀÇ 50% À̻󿡼­ ¹ÝÀÀÀÌ ³ªÅ¸³ª¸ç, ƯÀÌ IgE°¡ °ËÃâµÇ°í, IgE Ç×ü¼öÄ¡°¡ ³ôÀº °æ¿ìÀÇ Ç׿øÀ» ¸»ÇÑ´Ù.

    - ºÎ ¾Ë·¹¸£°Õ(Minor allergen) ; Á¶ Ç׿ø¿¡¼­ ¾Ë·¹¸£°ÕÀ¸·Î ÀÛ¿ëÇÏÁö¸¸ ȯÀÚÀÇ 50% ÀÌÇÏ¿¡¼­ ¹ÝÀÀÀ» ³ªÅ¸³»´Â Ç׿øÀ» ¸»ÇÑ´Ù. ÁÖ ¾Ë·¹¸£°ÕÀÌ ¾Æ´Ñ Ç׿ø¹°Áú.

    Der p 1

      • * ¼Ó¸íÀÇ ¿µ¹® ÀÌ´Ï¼È 3ÀÚ. Der ; Dermatophagoides ¸¦ À̸§
      • * Á¾¸íÀÇ ¿µ¹® ÀÌ´Ï¼È 1ÀÚ. p ; pteronyssinus ¸¦ À̸§
      • * ¹ß°ßµÈ ¾Ë·¹¸£°Õ ¼ø¼­ ¹øÈ£. 1 ; ù¹ø°·Î ¹ß°ßµÈ ¾Ë·¹¸£°Õ

    Der p 1, Der f 1

      ±¸Á¶ÀûÀ¸·Î À¯»çÇÑ °ÍÀº Á¾ÀÌ ´Ù¸£´õ¶óµµ µ¿ÀÏÇÑ ¹øÈ£¸¦ »ç¿ëÇÑ´Ù.

    Amb a 5.01

      µ¿ÀÏÇÑ Á¾³»¿¡¼­ ¾Æ¹Ì³ë»ê ¿°±â¹è¿­ÀÌ Â÷ÀÌ°¡ ÀÖ´Â isoallergen °æ¿ì¿¡´Â ¼Ò¼öÁ¡ 2ÀÚ¸® ¼ýÀڷΠǥ±âÇÑ´Ù. IsoallergenÀ̶õ IgE cross-linkingÀÇ »ó´çÇÑ ºÎÀ§¸¦ °øÀ¯ÇÏ´Â °°Àº ¾Ë·¹¸£°ÕÀÇ ´Ù¾çÇÑ ºÐÀÚÇüŸ¦ ¸»ÇÑ´Ù. IsoallergenÀÌ µÇ±â À§Çؼ­´Â ºñ½ÁÇÑ ºÐÀÚ Å©±âÀ̸ç, »ý¹°ÇÐÀû ±â´ÉÀÌ °°°í, ¾Æ¹Ì³ë»ê ¼­¿­ºÐ¼®¿¡¼­ 67% ÀÌ»ó °°¾Æ¾ß ÇÑ´Ù. À̸¦ ±âÀÔÇÒ ¶§¿¡´Â Bet v 1ÀÇ ´Ù¾çÇÑ IsoallergenÀ» Bet v 1.01, Bet v 1.21°ú °°ÀÌ ÇÑ´Ù.

    - Ã¥¿¡ ¾ð±ÞµÇ°í ÀÖ´Â ¾Ë·¹¸£°Õ ¸î °³ ¿¹Á¦

      Áý¸ÕÁö Áøµå±â

        Der p 1 ; Dermatophagoides pteronyssinus

        Der f 1 ; Dermatophagoides farinae

      °í¾çÀÌ

        Fel d 1 ; Felis domesticus

      °­¾ÆÁö

        Can f 1 ; Canis familiaris

      °õÆÎÀÌ

        Asp f 1 ; Aspergillus fumigatus

      °è¶õ

        Gad d 1 ; Gallus domesticus(Ovomucoid)

        Gda d 2 ; Gallus domesticus(Ovalbumin)

    * ºñ½ÁÇÑ À̸§ ±âÀÔ¹ý : °­¾ÆÁö(Canis domesticus) ¾Ë·¹¸£°ÕÀÎ Can d 1°ú °õÆÎÀÌÀÎ Candida albicansÀÇ ¿ë¾î°¡ Çì±ò¸± ¼ö Àֱ⿡ ÀÌ´Â Cand a 1 À̶ó°í ÇÑ´Ù.

    - ÃÖ±Ù¿¡´Â ÀÌ·¯ÇÑ ¾Ë·¹¸£°ÕÀÇ 3Â÷¿øÀû ºÐÀÚ±¸Á¶µéÀÌ ¹àÇôÁö°í ÀÖ´Ù. ¿¹¸¦µé¾î

    - ÀçÁ¶ÇÕ ¾Ë·¹¸£°ÕÀ̳ª È­ÇÐÇÕ¼º ¾Ë·¹¸£°ÕÀÌ ¾Ë·¹¸£°Õ°ú ±¸º°µÉ ÇÊ¿ä°¡ »ý±â°Ô µÇ¾ú´Ù. À̸¦À§ÇØ ÀçÁ¶ÇÕ ¾Ë·¹¸£°Õ(recombinant allergen)Àº ±ÛÀÚ¾Õ¿¡ 'r'À» ºÙÀÌ°í È­ÇÐÇÕ¼º(chemical synthetic) ¾Ë·¹¸£°ÕÀº 's'¸¦, ¾Ë·¹¸£°Õ(natural allergen)Àº 'n'À» ºÙÀδÙ. ¿¹¸¦µé¾î ÃÖ±Ù Áý¸ÕÁö Áøµå±â ¾Ë·¹¸£°ÕÀÇ ¸é¿ªÄ¡·á¸¦ À§ÇØ ÀçÁ¶ÇÕ ¾Ë·¹¸£°ÕÀ» »ç¿ëÇÏ¿© ¸é¿ªÄ¡·á ½Ãµµ°Ç¼ö°¡ Áõ°¡ÇÏ°í Àִµ¥ À̶§ Ç¥±â¹æ¹ýÀ» 'rDer p 1' À¸·Î ÇÑ´Ù. ÀÌ·¸°Ô »õ·Î ¸¸µç ¾Ë·¹¸£°ÕÀº ÀÚ¿¬ÀûÀÎ ¾Ë·¹¸£°ÕÀÇ 3Â÷¿øÀûÀÎ ±¸Á¶¿Í ´Ù¸£´Ù. ÀÚ¿¬ÀûÀÎ ¾Ë·¹¸£°ÕÀº À¯ÀüÁ¤º¸ÀÇ ¹ø¿ª ÈÄ º¯È¯°úÁ¤(post-translational modification)À» °ÅÃļ­ 3Â÷¿ø ±¸Á¶°¡ ¹Ù²î°Ô µÈ´Ù. ÀçÁ¶ÇÕ ¾Ë·¹¸£°ÕÀº ÀÌ·¯ÇÑ ±¸Á¶¿Í ´Ù¸¦ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ ±¸Á¶µµ ¶È°°ÀÌ ¸¸µç ¾Ë·¹¸£°ÕÀ» ±Û¸Ó¸®¿¡ 'rn' (recombinant natural), 'sn' (synthetic natural)À̶ó ºÙÀδÙ.

ºñ¸¸¼¼Æ÷´Â ¾Ë·¹¸£±â ¿°Áõ Ãʱ⿡ Áß¿äÇÑ È­Çй°ÁúÀ» ºÐºñÇÑ´Ù.

    - ´ëÇÑõ½Ä¹×¾Ë·¹¸£±â ÇÐȸ¿¡¼­´Â Mast cellÀÇ °ø½Ä¿ë¾î´Â 'ºñ¹Ý¼¼Æ÷'·Î ÇÑ´Ù. ÀÌ°÷¿¡¼­ »ç¿ëµÇ´Â ¿ë¾î´Â ÀÇÇÐȸ¿¡¼­ ¹ß°£µÈ ¿ë¾î·Î ÅëÀϽÃÄ×´Ù.

    - ¾Ë·¹¸£±â Á¶±â¹ÝÀÀ¿¡¼­ ºñ¸¸¼¼Æ÷(mast cell)¿Í È£¿°±â±¸(basophils)°¡ °¡Àå Áß¿äÇÑ ¼¼Æ÷ÀÌ´Ù. ±×·¯³ª ÀÌ·¯ÇÑ Á¶±â¹ÝÀÀÀÌ¿Ü¿¡µµ Èıâ¹ÝÀÀ¿¡µµ °ü¿©ÇÑ´Ù.

    - ºñ¸¸¼¼Æ÷´Â µÎ Á¾·ù°¡ ÀÖ´Ù. Çϳª´Â ÇǺÎ, Ç÷°ü, Àå(Intestine)ÀÇ Á¡¸·ÇÏ¿¡ Á¸ÀçÇÏ´Â MCTC¿Í Æó, ±â°üÁö, ¼ÒÀåÀÇ Á¡¸·¿¡ ÀÖ´Â MCT°¡ ÀÖ´Ù. MCT ´Â È÷½ºÅ¸¹Î°ú Tryptase ¸¸ ºÐºñÇÒ ¼ö ÀÖ´Ù. ¹Ý¸é¿¡ MCTC´Â È÷½ºÅ¸¹Î, Tryptase ¿Ü¿¡ Chymase, Carboxypeptidase, Cathepsin G µîÀ» ÇÔÀ¯ÇÏ°í ÀÖ´Ù.

    - ºñ¸¸¼¼Æ÷ÀÇ Æ¯Â¡Àº IgE ¿Í °áÇÕÇÏ´Â Fcepsilon RI(Fc epsilon Receptor I)ÀÌ ´Ù·® Á¸ÀçÇÑ´Ù´Â Á¡ÀÌ´Ù. ¼¼Æ÷´ç ÀÌ ¼ö¿ëü°¡ 10e4~10e6 Á¤µµ Á¸ÀçÁ¸´Ù. ¾Õ¼­ ¼³¸íÇÑ´ë·Î Fcepsilon R ´Â IgE ¿Í °áÇÕÇÏ´Â ¼ö¿ëüÀ̸ç ÀÌ¿¡´Â Fcepsilon RI °ú Fcepsilon RII°¡ ÀÖ´Ù. Fcepsilon RIÀº high affinity ¼ö¿ëüÀ̸ç Fcepsilon RII´Â low affinity ¼ö¿ëüÀÌ´Ù. ÀÌÀÇ marker ´Â CD23 ÀÌ´Ù. IgE¿Í °áÇÕÇÏ´Â Fcepsilon RIÀº ºñ¸¸¼¼Æ÷¿Í È£¿°±â±¸ ÀÌ¿Ü¿¡µµ ¼öÁö»ó¼¼Æ÷, ´Ü±¸¼¼Æ÷(Monocyte), ´ë½Ä¼¼Æ÷, È£»ê±¸¿¡µµ Á¸ÀçÇÑ´Ù. Fcepsilon R ¸¦ ÅëÇؼ­ IgE°¡ °áÇÕµÇ°í ±³Â÷¹ÝÀÀÀÌ ÀϾÀ¸·Î¼­ ¾Ë·¹¸£±âÀÇ Æ¯Â¡ÀûÀÎ Áõ»óÀÌ ³ªÅ¸³­´Ù.

    - ºñ¸¸¼¼Æ÷¿Í È£¿°±â±¸ ¼¼Æ÷¸·¿¡ IgE Fc ºÎÀ§°¡ ºÙ°ÔµÈ´Ù. ¾Ë·¹¸£°ÕÀÌ Ã¼³»¿¡ µé¾î¿Í ºñ¸¸¼¼Æ÷¸·¿¡ ºÙ¾îÀÖ´ø µÎ °³ÀÇ IgE¸¦ ¿¬°á(Cross-linking)½ÃÄѼ­ ¼¼Æ÷¸·ÀÇ Phospholipid ´ë»ç°úÁ¤À» ÅëÇÏ¿© ¼¼Æ÷ ³»¿¡ ¿©·¯ ½ÅÈ£¸¦ º¸³½´Ù.

    - ÇÑ ½ÅÈ£´Â °ú¸³(Ψأ:granule) µéÀ» ¼¼Æ÷¸·À¸·Î À̵¿½ÃŲ´Ù. À̸¦ Fusagenic ÁöÁúÀ̶ó ĪÇÑ´Ù.´Ù¸¥ ÇÑ ½ÅÈ£´Â CaÀ» ¼¼Æ÷³»·Î ²ø¾îµé¿© °ú¸³À» ¼¼Æ÷ ¹ÛÀ¸·Î ºÐºñÇϵµ·ÏÇÑ´Ù. ´Ù¸¥ ÇÑ ½ÅÈ£´Â ¾Æ¶óÅ°µ·»ê(Arachidonic acid)À» ¸¸µç´Ù. ÀÌ´Â ¾à¸®Çн𣿡 ¹è¿ö ±× ±âÀüÀ» Àß ¾Ë°í ÀÖÀ» °ÍÀÌ´Ù. ºñ¸¸¼¼Æ÷´Â ÀÌ·¯ÇÑ ¼¼ ½ÅÈ£Àü´Þ·Î È­Çй°ÁúÀ» ºÐºñÇÏ°Ô µÈ´Ù.

      ±×¸²¼³¸í) ºñ¸¸¼¼Æ÷ÀÇ IgE°¡ ¾Ë·¹¸£°Õ°ú ¹ÝÀÀÇÏ¸é ¼¼°¡Áö °æ·Î¸¦ ÅëÇؼ­ ´Ù¾çÇÑ È­Çй°ÁúÀ» ¹èÃâÇÏ´Â °ÍÀ» º¸¿©ÁÖ´Â ±×¸²ÀÌ´Ù. °úÁ¤ 1) °ú¸³À» ¼¼Æ÷º®À¸·Î À̵¿½ÃÅ°°í, °úÁ¤ 2)´Â Ä®½·À» Èí¼öÇÏ¿© ¼¼Æ÷¹ÛÀ¸·Î ¹èÃâÇϵµ·Ï µµ¿ÍÁÖ°í, °úÁ¤ 3)Àº Arachidonic acid °úÁ¤ÀÌ´Ù.

Á¶±â È­Çй°ÁúÀº Preformed mediators¿Í Newly formed mediators·Î ³ª´¶´Ù.

    - ºñ¸¸¼¼Æ÷¿¡¼­ ºÐºñµÇ´Â È­Çй°ÁúÀ» ÀÌ¹Ì ¸¸µé¾îÁø È­Çй°Áú(Preformed Mediators)°ú »õ·Ó°Ô ¸¸µé¾î¼­ ºÐºñÇÏ´Â È­Çй°Áú(Newly formed Mediators)À» ºÐ·ùÇϱ⵵ ÇÑ´Ù. ÀÌ¹Ì ¸¸µé¾îÁø È­Çй°Áú(Preformed Mediator)´Â ÀÚ±ØÀ» ¹Þ±â Àü¿¡ ÀÌ¹Ì ¼¼Æ÷³»ÀÇ °ú¸³¿¡¼­ ¸¸µé¾îÁö¾î ÀÖ¾î À̸¦ ºÐºñÇÏ´Â ÇüŸ¦ ¸»ÇÑ´Ù. »õ·Ó°Ô ¸¸µé¾îÁö¾î ºÐºñµÇ´Â ÇüÅ Áß Cystein leukotriene (À̸¦ sulfidoleukotriensÀ̶ó°íµµ ºÒ¸°´Ù, LTs)Àº ·ùÄÚÆ®¸®¿£ C4, D4, E4¸¦ À̸£¸ç À̸¦ ¾ïÁ¦ÇÏ´Â ¾Ë·¹¸£±â ¾à¹°·Î Ç×·ùÄÚÆ®¸®¿£Á¦°¡ ÀÖ´Ù. ÀÌ¿¡´Â Motelukast(Singulair TM)¿Í Planlukast (Onon TM)ÀÌ ÀÖ´Ù.

    - ÇÑ ºñ¸¸¼¼Æ÷¿¡¼­ ºÐºñµÇ´Â È÷½ºÅ¸¹Î ¾çÀº 2-5 pg Á¤µµÀÌ´Ù. Tryptase´Â ºñ¸¸¼¼Æ÷ÀÇ È°¼ºÈ­ Á¤µµ¸¦ ÆľÇÇϴµ¥ »ç¿ëµÇ±âµµ ÇÑ´Ù.

    Preformed Mediators

    • È÷½ºÅ¸¹Î (Histamine)
    • È¿¼Ò(Enzyme)
      • Neutral Proteases :Tryptase, Chymase, Carboxypeptidase
      • Acid Hydrolase : Arylsulfatase
      • Proteoglycan : Heparin, Chondroitin sulfate
    • Chemotactic factors
      • Eosinophil chemotactic factors(ECF)
      • Neutrophil chemotactic activity(NCA)

    Newly formed Mediators

    • Cyclooxygenase Products
    • Lipoxygenase Products
    • Platelet activating factor(PAF)
    • »çÀÌÅäÄ«ÀÎ : TNF-alpha, IL-5, IL-4, IL-6, IL-8

        ±×¸² ¼³¸í) ¾Æ¶óÅ°µ·»êÀÇ ´ë»ç°úÁ¤À» º¸¿©ÁÖ´Â ±×¸²ÀÌ´Ù. ¿ÞÂÊÀº Cyclooxygenase °úÁ¤ÀÌ°í ÀÌ´Â ¾Æ½ºÇǸ°¿¡ ÀÇÇØ ¾ïÁ¦µÇ¸ç ¿À¸¥ÂÊÀº Lipoxygenase °úÁ¤À» º¸¿©ÁØ´Ù. ÁÖ ´ë»ç¹°ÁúÀº ·ùÄÚÆ®¸®¿£ÀÌ°í ·ùÄÚÆ®¸®¿£ÀÇ °úÁ¤À» º¸¿©ÁÖ°í ÀÖ´Ù.

ºñ¸¸¼¼Æ÷´Â ´Ù¸¥ Àڱع°Áú¿¡¼­µµ ½±°Ô È­Çй°ÁúÀ» ½ñ¾Æ³½´Ù.

    - ºñ¸¸¼¼Æ÷´Â ºñ¸é¿ªÇÐÀûÀÎ Àڱع°Áú¿¡ ÀÇÇؼ­µµ È°¼ºÈ­µÈ´Ù. ¾Æ³ªÇʶô½Ã½º(Anaphylaxis)°¡ IgE ¹ÝÀÀ¿¡ ÀÇÇؼ­ ÀϾ´Â °ÍÀ̶ó¸é ¹æ»ç¼±Áֻ繰Áú(Iodide contrast material)À» ÁÖ»çÇÑ ÈÄ ºñ¸¸¼¼Æ÷°¡ È°¼ºÈ­µÇ¾î¼­ ¾Æ³ªÇʶô½Ã½º Áõ»óÀÌ ¹ßÇöµÇ±âµµ ÇÑ´Ù. À̸¦ ¾Æ³ªÇʶôÅäÀ̵å(Anaphylactoid)¶ó°í ÇÑ´Ù.

    - ºñ¸¸¼¼Æ÷¿Í °ü·ÃµÈ Áúº´¿¡´Â ¾Æ³ªÇʶô½Ã½º, Mastocytosis, Cutaneous Allergic reaction, ±â°üÁö õ½Ä°ú ºñ¿°, °üÀý¿° µîÀÌ ÀÖ´Ù.

È£»ê±¸´Â ¸¸¼º ¾Ë·¹¸£±â ¹ÝÀÀÀÇ ÁßÃßÀûÀÎ ¿ªÇÒÀ» ÇÑ´Ù.

    - È£»ê±¸(Eosinophil)´Â 1846³â ¹ß°ßµÈ ÀÌÈÄ ±â»ýÃæ °¨¿°°ú °ü·ÃÀÖ´Â °ÍÀÌ ¾Ë·ÁÁø ÈÄ ¾Ë·¹¸£±â ¹ÝÀÀ¿¡ ÁßÃßÀûÀÎ ¿ªÇÒÀ» ÇÏ´Â ¼¼Æ÷ÀÌ´Ù. È£»ê±¸ÀÇ »ý¼º, ºÐÈ­¿Í Apoptosis¿¡´Â GM-CSF, IL-3¿Í IL-5°¡ ÁÖ·Î °ü¿©Çϸç ÀÌÁß IL-5°¡ È£»ê±¸¼º »çÀÌÅäÄ«ÀÎÀ¸·Î ºÒ¸± Á¤µµ·Î È£»ê±¸ÀÇ ºÐÈ­°úÁ¤¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. °ñ¼ö¿¡¼­ ºÐÈ­ÇÏ´Â °úÁ¤ÀÌ ´ë·« 4ÀÏ Á¤µµ¼Ò¿äµÇ¸ç ´ëºÎºÐ Á¶Á÷³»¿¡ À¯ÀԵǰí Ç÷¾×À¸·Î´Â 1% ¹Ì¸¸ÀÌ ¹æÃâµÈ´Ù. ¹Ý°¨±â´Â 8-18½Ã°£ Á¤µµÀÌ´Ù.

    -È£»ê±¸ Ç¥¸é¿¡ IgE°¡ °áÇÕÇÒ ¼ö ÀÖ´Â FcepsilonRII°¡ ÀÖÀ¸¸ç ¾Ë·¹¸£°Õ¿¡ ÀÇÇØ IgE°¡ cross-linking ÀÌ ÀϾ¸é ´Ù¾çÇÑ ¹°ÁúÀº ºÐºñÇÑ´Ù.

    - Ãʱâ¹ÝÀÀ°ú ´Þ¸® Èıâ¹ÝÀÀÀº È£»ê±¸¿Í È£Áß±¸¿Í °°Àº ¼¼Æ÷µéÀÌ ¸ð¿©¼­ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â °ÍÀÌ´Ù. ¿¹¸¦µé¾î °õÆÎÀÌ°¡ ºñ¸¸¼¼Æ÷¿¡ ÀÇÇؼ­ ±â°üÁö ¼öÃàÀ» ÀÏÀ¸Ä×´Ù¸é ÀÌÈÄ È£»ê±¸, ¸²ÇÁ±¸µéÀÌ ¸ð¿©¼­ ¸¸¼º ±â°üÁö ¿°Áõ ¹ÝÀÀÀ» À¯µµÇÏ°Ô µÈ´Ù.

    - È£»ê±¸°¡ Ç¥Àû±â°ü¿¡ ¸ðÀÌ¸é ¿©·¯ È­Çй°ÁúÀ» ¹èÃâÇÏ°Ô µÈ´Ù. ÀÌ¿¡´Â °ú¸³ÇüÅÂÀÇ ´Ü¹éÁúÀ» Æ÷ÇÔÇÏ¿© »çÀÌÅäÄ«Àΰú È¿¼ÒµîÀÌ Æ÷ÇԵȴÙ.

    Ç¥. È£»ê±¸¿¡¼­ ºÐºñµÇ´Â È­Çй°Áú

    • Granule ´Ü¹éÁú
      • Major basic protein(MBP)
      • Eosinophil peroxidase(EPO)
      • Eosinophil cationic protein(ECP)
      • Eosinophil derived neurotoxin(EDN)
    • »çÀÌÅä Ä«ÀÎ
      • IL-1, IL-3, IL-4, IL-5, IL-6, GM-CSF¡¦.
    • Áö¹æ ´ë»ç»ê¹°(Lipid mediators)
      • ·ùÄÚÆ®¸®¿£, ÇÁ·Î½ºÅ¸±×¶õµò, PAF
    • È¿¼Ò
      • Charcot-Leyden crystal ´Ü¹éÁú, Collagenase, Elastase¡¦
    • Reactive oxygen intemediates
      • H2O2, Superoxide radical anion¡¦

    - ÀÌÁß ÀÓ»ó¿¡¼­ ECP(Eosinophil cationic protein) ÃøÁ¤ÇÏ¿© ¾Ë·¹¸£±â Á¤µµ¸¦ È®ÀÎÇϱ⵵ ÇÑ´Ù.

°á±¹ ¾Ë·¹¸£±â ¹ÝÀÀÀº ¿©·¯ ¼¼Æ÷°¡ °ü¿©ÇÏ¿© ÀϾ´Â °ÍÀÌ´Ù.

    - ¾Ë·¹¸£±â ¹ÝÀÀ¿¡´Â ´Ù¾çÇÑ ¼¼Æ÷µéÀÌ °ü¿©ÇÑ´Ù. ÀÌ¿¡´Â ºñ¸¸¼¼Æ÷, È£¿°±â±¸, È£»ê±¸, ¸²ÇÁ±¸, »óÇǼ¼Æ÷¿Í È£Áß±¸, ´ÜÇÙ±¸, ´ë½Ä¼¼Æ÷¿Í Ç÷¼ÒÆÇÀÌ °ü¿©ÇÑ´Ù.

      ±×¸² ¼³¸í) ´Ù¾çÇÑ ¼¼Æ÷ ÀÛ¿ëÀ¸·Î ¾Ë·¹¸£±â°¡ ÀϾ´Â °ÍÀ» º¸¿©ÁÖ°í ÀÖ´Ù. ¾Ë·¹¸£°ÕÀ» ¼öÁö»ó¼¼Æ÷°¡ T ¸²ÇÁ±¸¿¡ Àü´ÞÇÏ°í T ¸²ÇÁ±¸´Â B ¸²ÇÁ±¸¿Í ÇÔ²² IgE¸¦ ¸¸µé°í ÀÌ´Â ºñ¸¸¼¼Æ÷¿Í È£¿°±â±¸ ¼¼Æ÷º®¿¡ ºÙ¾îÀÖ´Ù°¡ ´Ù¾çÇÑ È­Çй°ÁúÀ» ¹èÃâÇÑ´Ù. È£»ê±¸ ¶ÇÇÑ ´Ù¾çÇÑ ¾Ë·¹¸£±â È­Çй°ÁúÀ» ¹èÃâÇÏ¸ç »óÇǼ¼Æ÷¿¡ ¿µÇâÀ» ÁØ´Ù.

    - ¼¼Æ÷ ¹ÝÀÀÀ» ÀÌÇØÇÏ¿´´Ù¸é, ¼¼Æ÷ ÀÛ¿ë¿¡ ÀÇÇÑ ´ÙÀ½À» ¼³¸íÇØ º¸ÀÚ. 6°³¿ù µÈ ¾ÆÀÌ°¡ ´Þ°¿À» ¸Ô°í ¾ó±¼ÀÌ »õÆÄ·¡Áø´Ù°í ÀÀ±Þ½Ç¿¡ ³»¿øÇÏ¿´´Ù. ÀÌ ¾ÆÀÌ ¸ö¿¡¼­ ÀϾ ¸é¿ª ¹ÝÀÀÀ» ¼³¸íÇØ º¸ÀÚ.

    - ÀÌ¿¡´Â È£Áß±¸µµ Æ÷ÇԵȴÙ. È£Áß±¸´Â ±â°üÁö õ½ÄÀ¸·Î »ç¸ÁÇÑ È¯ÀÚÀÇ Á¶Á÷°Ë»ç¿¡¼­ È£»ê±¸º¸´Ù ħÀ±ÀÌ ¸¹ÀÌ º¸ÀÌ´Â ¼¼Æ÷ÀÌ´Ù. ¶ÇÇÑ È£Áß±¸´Â TGF-b¿Í MMP-9 À» »ý»êÇÏ¿© ±âÀú¸·ÇÏ µÎ²² Áõ°¡¿Í °°Àº ±âµµ °³Çü°ú °ü°èÀÖ´Ù. ±Þ¼º ÁßÁõ õ½Ä ¹× ¸¸¼º õ½Ä ȯÀÚÀÇ °´´ã¿¡¼­ È£Áß±¸¼ö´Â Áõ°¡ÇÏ¿´´Ù.

¾Ë·¹¸£±â ¹ÝÀÀÀº µÎ°¡Áö·Î ³ª´¶´Ù. Á¶±â ¹ÝÀÀ°ú Èı⠹ÝÀÀ.

    soon....

¾Æ·¡ ³»¿ëÀº ÇлýµéÀÌ ¾ËÁö ¸øÇصµ ½ÃÇ躸´Âµ¥ ÁöÀåÀÌ ¾ø´Â ³»¿ëÀÓ.

 

¸é¿ª ¹ÝÀÀÀ» 7°¡Áö·Î ¼¼ºÐÇÒ ¼ö ÀÖ´Ù.

    - 1960³â´ë ¸¸µé¾îÁø Gell and Coombs ºÐ·ù´Â ¸é¿ª¹ÝÀÀÀÌ º¹ÀâÇÑ °ÍÀÌ ¹àÇôÁö¸é¼­ Á»´õ ´Ù¾çÇÑ ¼¼ºÐÈ­°¡ ÇÊ¿äÇÏ°Ô µÇ¾ú´Ù. ¿¹¸¦µé¾î ¾Ë·¹¸£±â ¹ÝÀÀÀº Á¦ 1Çü ¹ÝÀÀ°ú Á¦ 4Çü ¹ÝÀÀÀÇ È¥ÇÕ¹ÝÀÀÀÌ´Ù. ¿¹¸¦µé¾î ¾ÆÅäÇÇÇǺο°Àº IgE ¸Å°³¹ÝÀÀÀÌÁö¸¸ ´õ Áß¿äÇÑ °ÍÀº T ¼¼Æ÷°¡ °ü¿©ÇÑ´Ù´Â Á¡ÀÌ´Ù. ÀÌ·¯ÇÑ ¹®Á¦Á¡À» ÇØ°áÇÑ ºÐ·ù¹ýÀÌ 7ÇüÀ¸·Î ³ª´« °ÍÀÌ´Ù. À̸¦ SellÀÌ Á¦¾ÈÇÏ¿´´Ù°í ÇÏ¿©¼­ Sell ºÐ·ù¹ýÀ̶ó°í ÇÑ´Ù. (1996³â Clinical Immunology:principles and practice Ã¥ÀÚ¿¡)

    1. Inactivation/activation antibody reactions
    2. ÀÌ´Â IIb/IV·Î ¾Ë·ÁÁø ¹ÝÀÀÀÌ´Ù. È£¸£¸ó, È£¸£¸ó ¼ö¿ëü, È¿¼Ò, ¾à¹°µîÀÌ Áúº´À» ÀÏÀ¸Å°±âµµ ÇÏ°í ¾ïÁ¦Çϱ⵵ ÇÏ´Â ÀÛ¿ëÀ» ¼³¸íÇϴµ¥ »ç¿ëµÈ´Ù. Á¦ 2/7Çü°ú ´Þ¸® ¼¼Æ÷µ¶¼º¹ÝÀÀÀº ÀϾÁö ¾Ê°í ¼ö¿ëü¸¦ ÀÛ¿ëÁ¦/±æÇ×Á¦ ¿ªÇÒÀ» ÇÒ ¼ö°¡ ÀÖ´Ù.

    3. Cytotoxic or cytolytic antibody reactions
    4. ÀÌ´Â IIa/IV ¹ÝÀÀÀ¸·Î ¾Ë·ÁÁö¾ú´Ù. ¼¼Æ÷ µ¶¼ºÀ» ³ªÅ¸³»´Â °ÍÀ¸·Î opsonization, º¸Ã¼ È°¼ºÈ­ ¶Ç´Â ADCC ¹ÝÀÀ¿¡ ÀÇÇؼ­ ÀûÇ÷±¸, Ç÷¼ÒÆÇÀÌ ±úÁ®³ª°¡´Â °ÍÀ» ¸»ÇÑ´Ù.

    5. Immune complex reactions
    6. ÀÌ´Â III/IV Çü°ú °°´Ù.

    7. Allergic reactions
    8. Type I°ú Type IV ¹ÝÀÀ¿¡¼­ ¾Ë·¹¸£±âÀÇ Æ¯Â¡ÀûÀÎ Çö»óÀ» ¸ð¾Æ³õÀº °ÍÀÌ´Ù.

    9. Cell mediated Cytotoxicity
    10. ÀÌ´Â T¼¼Æ÷³ª NK¼¼Æ÷¿¡ ÀÇÇÑ ¹ÝÀÀÀ» ¸»ÇÑ´Ù. CD8+ ¼¼Æ÷°¡ ¹ÙÀÌ·¯½º¿¡ ´ëÇؼ­ ¹æ¾î±âÀüÀ¸·Î ÀÛµ¿ÇÏ´Â °ÍÀ̳ª NK ¼¼Æ÷°¡ ¾Ï¼¼Æ÷¿¡´ëÇؼ­ °¨½ÃÈ°µ¿À» ÇÏ´Â °ÍÀÌ ¿¹Á¦ÀÌ´Ù.

    11. Delayed hypersensitivity reactions
    12. ÀÌ´Â IVa/IV ¹ÝÀÀÀ¸·Î T ¼¼Æ÷°¡ ƯÁ¤ÇÑ Ç׿ø¿¡ ¹Î°¨ÇÏ°Ô ÀÛ¿ëÇÏ¿© ÀÓ»ó Áõ»óÀÌ ³ªÅ¸³ª´Â °ÍÀÌ´Ù. Á¢Ã˼º ÇǺο°ÀÌ ´ëÇ¥ÀûÀ̸ç ÀÌ ¶ÇÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀÌ¶ó ¿©°ÜÁöÁö¸¸ CD4+ ¼¼Æ÷°¡ ¾Ë·¹¸£±â ÀÛ¿ë°ú ´Ù¸£°Ô Th1 ¹ÝÀÀÀÌ ÁÖ·Î ÀϾ´Ù´Â Á¡¿¡¼­ ´Ù¸£´Ù.

    13. Granulomatous reactions
    14. ÀÌ´Â IVb/IV¸¦ À̸¥´Ù.

     

Ç׿øÀº ¼¼°¡Áö ¹æ¹ýÀ¸·Î Æ÷ȹµÈ´Ù.

    - ¹Ì¼º¼÷ÇÑ ¼öÁö»ó¼¼Æ÷´Â ¸î °¡Áö ¹æ¹ýÀ¸·Î ¿ÜºÎÇ׿øÀ» ¼·ÃëÇϴµ¥ ÀÌ¿¡´Â

    1. ¹Ì¸³ÀÚ Å©±âÀÇ Ç׿øÀ» ¼·ÃëÇÏ´Â Æ÷½ÄÀÛ¿ë(Phagocytosis),
    2. ¼¼Æ÷»À´ë(cytoskeleton)À» È°¿ëÇÑ ¼¼Æ÷¸· ruffling¿¡ ÀÇÇÑ ¼¼Æ÷³»ÀÌÀÔ ÀÛ¿ëÀ» ÇÏ´Â À½¼¼Æ÷ÀÛ¿ë(Pinocytosis; ¼¼Æ÷Èí¼öÀÛ¿ë)°ú
    3. ¼ö¿ëü¸Å°³ ¼¼Æ÷³»ÀÌÀÔ(Receptor-mediated endocytosis)ÀÛ¿ëÀÌ ÀÖ´Ù.

    - À½¼¼Æ÷ÀÛ¿ëÀº 0.2 um ÀÌÇÏ Å©±âÀÇ Ã¼¾×À» Èí¼öÇÏ´Â ¹Ì¼¼À½¼¼Æ÷ÀÛ¿ë(micropinocytosis)°ú À̺¸´Ù Å« À¯µ¿¼º ¹°ÁúÀ» Èí¼öÇÏ´Â °Å´ëÀ½¼¼Æ÷(macropinocytosis)·Î ³ª´¶´Ù. ¼öÁö»ó¼¼Æ÷¿¡¼­´Â ¹Ì¼¼À½¼¼Æ÷Àۿ뺸´Ù °Å´ëÀ½¼¼Æ÷ÀÛ¿ëÀÌ MHC class I °ú II ºÐÀÚ·Î Ç׿øÀ» Á¦½ÃÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù.

    - Ç׿øÁ¦½Ã¼¼Æ÷´Â ³»ºÎ Ç׿ø°ú ¿ÜºÎ Ç׿øÀ» ´Ù¸£°Ô ÀνÄÇÑ´Ù. Ç׿øÀÌ ¼¼Æ÷ ³»ºÎ¿¡ Àִ°¡, ¿ÜºÎ¿¡ Àִ°¡¿¡ µû¶ó Ç׿øÁ¦½Ã¼¼Æ÷°¡ T ¼¼Æ÷¿¡ Àü´ÞÇÏ´Â ¹æ½ÄÀÌ ¾à°£ ´Ù¸£´Ù. ¼¼Æ÷Áú ³»¿¡ ÀÖ´Â Ç׿øÀº, ¿¹¸¦µé¾î ¹ÙÀÌ·¯½º³ª Á¾¾ç, ¼¼Æ÷³»¿¡ ±â»ýÇÏ´Â ¼¼±ÕÀº MHC Class I °ú °áÇյǾî T ¼¼Æ÷¿¡ Àü´ÞµÈ´Ù. ÀÌ´Â ¼¼Æ÷µ¶¼º T¼¼Æ÷(CD8 T cells, Cytotoxic T cells, Tc)¸¦ À¯µµÇÏ¿© °¨¿°µÈ ¼¼Æ÷(MHC I Ç¥Çö¼¼Æ÷, ÇÙÀ» °¡Áø ¸ðµç ¼¼Æ÷°¡ Ç¥Çö °¡´É)¸¦ Á×ÀÌ°Ô µÈ´Ù. ¼¼Æ÷ ¿Ü¿¡ ÀÖ´Â Ç׿ø, ¿¹¸¦µé¾î µ¶¼º¹°Áú, ¹Ì»ý¹°, ¾à¹° µîÀº Æ÷½ÄµÇ¾î LysosomÀÇ MHC II ¿¡ ÀÇÇØ ¹ßÇöµÇ°í º¸Á¶ T¼¼Æ÷(CD4 T cells, helper T cells, Th)¿¡ ½ÅÈ£Àü´ÞÀÌ ÀϾ´Ù. MHC II´Â Ç׿øÁ¦½Ã¼¼Æ÷¿¡¼­¸¸ Ç¥ÇöµÈ´Ù.

    - ¼öÁö»ó¼¼Æ÷´Â º´¿øü ƯÀÌ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Ù. 1998³â óÀ½À¸·Î º´¿øüÀÇ µ¶¼ÒÀÎ LPS(Lipopolysaccharide)¸¦ ¼öÁö»ó¼¼Æ÷°¡ ¾î¶»°Ô ÀνÄÇÏ´ÂÁö ¾Ë°Ô µÇ¾ú´Ù. ÀÌ ¹ÝÀÀ¿¡´Â CD14, TLR4¿Í MD-2°¡ °ü¿©ÇÏ´Â °ÍÀ¸·Î º¸°íµÇ¾úÀ¸¸ç, ÀÌÈÄ ÃÖ±Ù±îÁö ¡®Toll Rush¡¯ ±¤Ç³ÀÌ ºÒ¸ç ÇöÀç 11°³ÀÇ TLR(Toll like receptors)°¡ ¹àÇôÁ³´Ù. ¼öÁö»ó¼¼Æ÷´Â º´¿øüÀÇ °øÅëµÈ ÆÐÅÏ(PAMPs ; Pathogen-associated molecular patterns)À» ¼öÁö»ó¼¼Æ÷ÀÇ Æ¯Á¤ÇÑ ¼ö¿ëü¿¡¼­(PRR ; Pattern recognition receptors) ÀνÄÇÏ°Ô µÇ¸ç, ÀÌÁß TLR°¡ °¡Àå ¸¹ÀÌ ¾Ë·ÁÁ³´Ù. ¿¹¸¦µé¾î LPS´Â TLR Áß TLR4 °¡ ÀνÄÀ» ÇÏ¿© ¹ÝÀÀÇÏ°Ô µÈ´Ù. RS¹ÙÀÌ·¯½ºÀÇ F ´Ü¹éÁúÀº TLR4¸¦ ÅëÇØ, ¸¶ÀÌÄÚÇöóÁ ±ÕÀº TLR2/TLR6·Î, °áÇÙ±Õ(Mycobacteria)´Â TLR2·Î Àνĵȴٴ °ÍÀÌ´Ù. Áï ƯÀÌÇÑ º´¿øü¸¸À» ÀνÄÇÏ´Â ºÐÈ­µÈ T¼¼Æ÷ó·³ ¼öÁö»ó¼¼Æ÷µµ ƯÁ¤ ±ÕÁÖ¸¦ °íÀ¯ÇÑ ¼ö¿ëü¸¦ ÅëÇؼ­ ÀνÄÇÑ´Ù´Â °ÍÀÌ´Ù.

¿ÜºÎÇ׿ø Áß ¼öÁö»ó¼¼Æ÷´Â Pathogen°ú ¾Ë·¹¸£°ÕÀ» ´Ù¸£°Ô ÀνÄÇÑ´Ù.

    - ¼öÁö»ó¼¼Æ÷°¡ ¿ÜºÎ Ç׿øÀÇ ÆÐÅÏÀ» ÀνÄÇÏ´Â PRRÀº ¼¼ Á¾·ù°¡ ÀÖ´Ù.

    • ºÐºñ¼º PRR ; mannan binding lectin
      • ¹Ì»ý¹°ÀÇ Åº¼öÈ­¹°°ú °áÇÕÇØ ¹Ì»ý¹°ÀÌ º¸Ã¼°è¿Í Ž½Ä¼¼Æ÷¿¡ ÀÇÇØ Àνĵǵµ·Ï ¸¸µå´Â ¿É¼Ò´Ñ ±â´ÉÀ» ÇÑ´Ù.
    • ¼¼Æ÷³» ÀÌÀÔ PRR ; Langerin, DC-SIGN, BDCA2, Dectin-1, Mannose receptor µî.
      • ¹Ì»ý¹°ÀÇ Æ¯Â¡ÀÎ mannose¸¦ °¡Áø ź¼öÈ­¹°À» ÀνÄÇÏ¿© Ž½ÄÀÛ¿ëÀ» ¸Å°³ÇÑ´Ù. ÀÌ¿¡´Â Scavenger ¼ö¿ëü·Î ¾Ë·ÁÁø °ÍµéÀÌ(C-type lectin, CLR) Æ÷ÇԵȴÙ. Ž½ÄµÈ Ç׿øÀº ÆÄ°íÁ»(Phagosome)À» ÅëÇؼ­ ¸®¼ÒÁ»°ú °áÇյǰí Æı«µÇ¾î MHC II ·Î Ç¥ÇöµÈ´Ù.
    • ½ÅÈ£Àü´Þ PRR ; TLR1 ~ 11
      • º´¿øü ƯÀÌ ¼ö¿ëü¸¦ ÅëÇؼ­ ¿°Áõ¼º »çÀÌÅäÄ«ÀÎÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Á¾·ùÀÇ ¸é¿ª¹ÝÀÀ À¯ÀüÀÚ¸¦ Ç¥ÇöÇϵµ·Ï À¯µµÇÏ´Â ½ÅÈ£Àü´Þ°æ·Î¸¦ È°¼ºÈ­ ½ÃŲ´Ù.
        • ¿°Áõ¼º »çÀÌÅäÄ«ÀÎ À¯µµ
        • °øµ¿ÀڱغÐÀÚÀÎ B7.1/CD80À» È°¼ºÈ­

    - ¾Ë·¹¸£°ÕÀº ½ÅÈ£Àü´Þ PRR·Î ÀνĵÇÁö ¾ÊÀ¸¸ç À§ÇèÇÑ µ¶¼º¹°Áú·Î ÀνĵÇÁöµµ ¾Ê´Â´Ù. ¼¼Æ÷³» ÀÌÀÔ PRR ÀÇ ÀÏÁ¾ÀÎ Mannose ¼ö¿ëü, FceRI ¼ö¿ëü¸¦ ÅëÇؼ­ T ¼¼Æ÷¿¡ Àü´ÞµÇ°Ô µÈ´Ù. À̶§ IL-12 ¿Í °°Àº »çÀÌÅäÄ«ÀÎÀÌ ºÐºñµÇÁö ¾ÊÀ¸¹Ç·Î Th2 ¹ÝÀÀÀÌ À¯µµµÈ´Ù.

    - ÀÚ°¡ ´Ü¹éÁú°ú ¾Ë·¹¸£°ÕµéÀº Scavenger ¼ö¿ëüµé¿¡ ÀÇÇؼ­ À§Çè½ÅÈ£·Î ¹Þ¾Æµé¿©ÁöÁö ¾Ê°í ¹«½Ã(Ignore) µÈ´Ù. ¾î¶² ¿øÀÎÀ¸·Î, ¿¹¸¦µé¾î °¨¿°ÀÌ °°ÀÌ µÇ¸é ÀÚ°¡ ´Ü¹éÁúÀ̳ª ¾Ë·¹¸£°ÕÀ» ¹Ì»ý¹°°ú °°ÀÌ À§Çè½ÅÈ£·Î ó¸®ÇÏ°Ô µÇ°í ÀÌ¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀÌ À¯µµµÉ ¼ö ÀÖ´Ù.

    - Ç׿øÁ¦½Ã¼¼Æ÷ÀÇ °¡Àå °­·ÂÇÑ ±â´ÉÀº ¼öÁö»ó¼¼Æ÷°¡ ¼öÇàÇÑ´Ù. ÀÎü ³»¿¡ Ç׿øÀÌ µé¾î¿ÔÀ» ¶§ µÎ °¡Áö ¹ÝÀÀÀÌ ÀϾ ¼ö ÀÖ´Ù. Çϳª´Â Æ÷½ÄµÇ¾î ¼ÒÈ­µÇ°Å³ª °ü¿ë(Tolerance)ÀÌ ÀϾ°Å³ª ´Ù¸¥ Çϳª´Â ½ÅÈ£Àü´Þ µÇ¾î ÀûÀÀ¸é¿ªÀ» À¯µµÇÏ´Â °ÍÀÌ´Ù. Ç׿øÀ» Æ÷½ÄÇÏ´Â ¼¼Æ÷´Â ÁַΠȣÁß±¸·Î ´ëÇ¥µÇ´Â °ú¸³±¸¿Í ´ë½Ä¼¼Æ÷°¡ °ü¿©ÇÑ´Ù.

    - Ç׿øÁ¦½Ã¼¼Æ÷(APC, Antigen presenting cell)Àº ´ë½Ä¼¼Æ÷, B¼¼Æ÷¿Í ¼öÁö»ó¼¼Æ÷(Dendritic cell, °¡Áö¼¼Æ÷, µ¹±â¼¼Æ÷)°¡ ÀÖ´Ù. ÀÌÁß ¼öÁö»ó¼¼Æ÷°¡ T ¼¼Æ÷¿¡ °¡Àå °­·ÂÇÑ ½ÅÈ£Àü´Þ ´É·ÂÀ» °¡Áö°í ÀÖ´Ù. Ç׿øÀÌ Æ÷½ÄµÇ¾î ¼ÒÈ­µÇ±âµµ ÇÏÁö¸¸ ¼öÁö»ó¼¼Æ÷¸¦ ÅëÇؼ­ T¼¼Æ÷¿¡ Àü´ÞµÇ±âµµ ÇÑ´Ù. Àü´ÞµÈ ½ÅÈ£´Â ¹«Àå¼¼Æ÷(Effector T cell)ÀÌ µÇ±âµµ ÇÏ°í ±â¾ï¼¼Æ÷(Memory T cells)ÀÌ µÇ±âµµ Çϸç B ¼¼Æ÷¿Í »óÈ£ÀÛ¿ëÀ¸·Î IgE¸¦ ¸¸µé¾î ³»±âµµ ÇÑ´Ù. ¼öÁö»ó¼¼Æ÷¸¦ ÅëÇØ T¼¼Æ÷¿¡ ¼¼°¡Áö ½ÅÈ£ Àü´ÞÀÌ ÀÌ·ïÁö°í T ¼¼Æ÷´Â Th1, Th2 ¶Ç´Â Th0·Î ºÐÈ­ÇÑ´Ù.

    ±×¸²) ¼öÁö»ó¼¼Æ÷´Â ¿ÜºÎ º´¿øü·ÎºÎÅÍ ÀÚ±ØÀ» ¹ÞÀ¸¸é ±Þ¼ÓÇÏ°Ô Æ÷ȹ´É·Â°ú Ç׿ø󸮴ɷÂÀ» ¼Ò½ÇÇϸ鼭 ±¹¼Ò ¸²ÇÁÀý·Î À̵¿ÇÏ¿© 3°¡Áö ½ÅÈ£¸¦ ¹Ì°æÇè T ¸²ÇÁ±¸¿¡ Àü´ÞÇÏ¿© ¼¼Æ÷Áõ½Ä°ú ºÐÈ­¸¦ À¯µµÇÑ´Ù. ¼öÁö»ó¼¼Æ÷¿¡¼­ Æ÷ȹÇÑ º´¿øü¸¦ ÆéŸÀ̵å(peptide)·Î ó¸®ÇÏ¿© ÁÖÁ¶Á÷Á¢ÇÕº¹ÇÕü(Major Histocompatibility Complex ; MHC)¸¦ ÅëÇØ T cell receptors(TCR)¿¡ Àü´ÞÇÏ´Â °ÍÀÌ Á¦ 1½ÅÈ£Àü´ÞÀÌ´Ù. ¸¸ÀÏ Á¦ 1½ÅÈ£Àü´ÞÀÌ ¾ÈµÇ¸é ÀڱؿøÀ» ÀνÄÇÏÁö ¸øÇÑ °ÍÀ¸·Î À̸¦ ¸é¿ªÇпë¾î·Î ¹«½Ã(ignore)¶ó ÇÑ´Ù. Á¦ 2½ÅÈ£Àü´ÞÀÎ °øµ¿ÀڱؽÅÈ£(Co-stimulatory signals)´Â CD80/CD28 °áÇÕÀ¸·Î ´ëÇ¥µÇ´Â ¹ÝÀÀÀ¸·Î ÀÌ ¹ÝÀÀÀÌ ÀϾÁö ¾ÊÀ¸¸é ¾Æ³ÊÁö(anergy) »óŶó°í ÇÑ´Ù. Á¦ 1, 2 ½ÅÈ£¿Í ´Þ¸® Á¦ 3ÀÇ ½ÅÈ£´Â T¼¼Æ÷ ¸é¿ª ÆíÇâÀ» À¯µµÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ±× Áß IL-12¿¡ ÀÇÇؼ­ Th1ÀÌ À¯µµµÇ´Â °ÍÀÌ °¡Àå Àß ¾Ë·ÁÁ® ÀÖÁö¸¸, Th2°¡ ¾î¶² ½ÅÈ£Àü´Þ¿¡ ÀÇÇؼ­ À¯µµµÇ´ÂÁö´Â È®½ÇÇÏÁö ¾Ê´Ù.

Th1/Th2 Æз¯´ÙÀÓ

    - Th ¼¼Æ÷°¡ µÎ Á¾·ù°¡ ÀÖ´Ù. Çϳª´Â IFN-g¸¦ ºÐºñÇÏ´Â Th ¼¼Æ÷ÀÌ°í ´Ù¸¥ Çϳª´Â IL-4 ¸¦ ºÐºñÇÏ´Â ¼¼Æ÷ÀÌ´Ù. À̸¦ °¢°¢ Th1, Th2 ¼¼Æ÷¶ó À̸¥´Ù. º¸Á¶¼¼Æ÷¶ó´Â °³³äÀº T ¼¼Æ÷°¡ B ¼¼Æ÷¸¦ µµ¿Í¼­ Ç×ü¸¦ ¸¸µç´Ù´Â °³³ä¿¡¼­ ³ª¿Ô°í ÀÌ´Â Th2 ¼¼Æ÷ÀÇ ÁÖ¿ä ±â´ÉÀÌ´Ù. ÀÌ´Â ¼¼Æ÷ ¿Ü Ç׿øÀ» ÀÎÁöÇÏ¿© Æı«Çϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. Th1 ¼¼Æ÷´Â ¼¼Æ÷ ³» ¼ÒÆ÷¿¡ ¼­½ÄÇÏ´Â °áÇÙ±Õ°ú °°Àº ±ÕÁÖ¸¦ Á×À̱â À§ÇØ ´ë½Ä¼¼Æ÷¸¦ µµ¿ÍÁÖ´Â ¿ªÇÒÀ» ÇÑ´Ù.

    - Th1¼¼Æ÷¿Í Th2 ¼¼Æ÷´Â »óÈ£ Á¶ÀýÇÑ´Ù´Â °³³äÀº Áß¿äÇÑ ¾Ë·¹¸£±â ±âÀü °³³äÀ¸·Î ¼³¸íµÇ°í ÀÖ´Ù.

    - Th2 ¼¼Æ÷ÀÇ Æ¯Â¡Àº ¾Ë·¹¸£±â¸¦ À¯¹ßÇÒ ¼ö ÀÖ´Â »çÀÌÅäÄ«ÀÎÀ» ºÐºñÇÑ´Ù´Â Á¡ÀÌ´Ù. ÀÌ¿¡´Â IL-4, IL-5 ¿Í IL-13 µîÀÌ ÀÖ´Ù.

    - IL-4 ÀÇ ¾Ë·¹¸£±â ¹ÝÀÀ¿¡¼­ °¡Àå Áß¿äÇÑ ±â´ÉÀº B¼¼Æ÷¸¦ µµ¿ÍÁÖ´Â ¿ªÈ°ÀÌ´Ù.

    • 1) B ¼¼Æ÷ È°¼ºÈ­
    • 2) B ¼¼Æ÷ ºÐ¿­(proliferation)
    • 3) B¼¼Æ÷ ºÐÈ­À¯µµ(IgE, IgG1À¸·Î Class switch)
    • 4) CD4¼¼Æ÷¸¦ Th2 ¼¼Æ÷·Î À¯µµÇÑ´Ù.

    - IL-5Àº °­·ÂÇÑ È£»ê±¸ À¯µµ¹°ÁúÀÌ´Ù.

    - Th1 ¿¡¼­ ºÐºñµÇ´Â IFN-g°¡ Th2¸¦ Counter regulate ÇÏ°í IL-4µµ ±×·¯ÇÑ ¿ªÇÒÀ» ÇÑ´Ù°í ¼³¸íµÇ´Â ÀÌ·ÐÀº 1990³â´ë ³Î¸® ¹Þ¾Æµé¿©Á³´Ù.

    - À§»ýÀÌ·ÐÀº ¾Ë·¹¸£±â Áõ°¡¸¦ ¼³¸íÇÏ´Â Áß¿äÇÑ °³³äÀÌ´Ù. 1990³â´ë ¿ªÇÐÁ¶»ç¸¦ ÅëÇؼ­ ÇüÁ¦ ¼ø¿¡ µû¶ó ¾Ë·¹¸£±â À¯º´À²ÀÌ Â÷ÀÌ°¡ ³­´Ù´Â °ÍÀ» ¾Ë°ÔµÇ¾ú´Ù. ÀÌÈÄ °¨¿°¿¡ °É¸° ȯÀÚ¿¡¼­ ¾Ë·¹¸£±â ¹ß»ýºóµµ°¡ Àû´Ù´Â °ÍÀ» ¾Ë°í Th1/Th2 Æз¯´ÙÀÓÀ» È°¿ëÇÏ¿© 'À§»ýÀÌ·Ð'À» ¸¸µé¾ú´Ù. Áï °¨¿°ÀÌ ¸¹À¸¸é ¾Ë·¹¸£±â°¡ °¨¼ÒÇÑ´Ù´Â °ÍÀÌ´Ù.

    - ±×·¯³ª ÀÌ·¯ÇÑ Æз¯´ÙÀÓµµ º¯È­¸¦ °Þ°í ÀÖ´Ù. 1990³â´ë Áß¹Ý ÀÌÈÄ¿¡ Th1/Th2 Æз¯´ÙÀÓ°ú ¸ð¼øµÇ´Â °á°úµéÀÌ ¹ßÇ¥µÇ¾ú´Ù.

    • ¿ªÇÐÁ¶»ç¿¡¼­ Th1 ¸é¿ª¹ÝÀÀÀ¸·Î ¹ß»ýÇÑ´Ù°í ¿©°ÜÁö´Â ´Ù¹ß¼º °æÈ­Áõ°ú ·ù¸¶Æ¼½º °üÀý¿°È¯ÀÚ¿¡¼­ ¾Ë·¹¸£±â ÁúȯÀÌ °¨¼ÒÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ³´Âµ¥, ÀÌ¿Í ´Þ¸® ÃÖ±Ù 20¿©³âµ¿¾È ¾Ë·¹¸£±â ÁúȯÀÌ Áõ°¡ÇÑ °Í°ú ¸¶Âù°¡Áö·Î Th1 Áúº´ÀÌ¶ó ¿©°ÜÁö´Â ÀÚ°¡¸é¿ªÁúȯµé, Á¦ 1Çü ´ç´¢º´µµ °°ÀÌ Áõ°¡ÇÏ¿´´Ù.
    • ¶ÇÇÑ ±â»ýÃæ °¨¿°Àº Th2 ¸é¿ª±âÀü¿¡ ÀÇÇؼ­ À¯µµµÇ°í ÀÌ¿¡ µû¶ó ¾Ë·¹¸£±â Áúº´À» Áõ°¡½Ãų °ÍÀÌ¶ó ¿©°ÜÁöÁö¸¸ ¿ÀÈ÷·Á ¾Ë·¹¸£±â ¹ß»ýÀ» ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
    • ¼¼¹ø°·Î´Â Th1ÀÇ »çÀÌÅäÄ«ÀÎÀÎ IFN-g°¡ ¾Ë·¹¸£±â ¿°Áõ¹ÝÀÀ¿¡ Á¸ÀçÇϸç Áúº´ ÁøÇà¿¡ ±í¼÷È÷ °ü¿©ÇÑ´Ù´Â Á¡ÀÌ ¸¶¿ì½º¿¬±¸¿Í Àӻ󿬱¸ °á°ú ¹àÇôÁ³´Ù

    - ÀÌ·¯ÇÑ Æз¯´ÙÀÓÀº rT ¼¼Æ÷ÀÇ ¹ß°ßÀ¸·Î ´ÙÀ½°ú °°ÀÌ º¯ÇÏ°í ÀÖ´Ù.

      ±×¸² ¼³¸í) Th1/Th2 Æз¯´ÙÀÓÀ» º¸¿©ÁÖ°í ÀÖ´Ù. Th1ÀÌ ¿ì¼¼ÇÏ¸é ¾Ë·¹¸£±â ¹ÝÀÀÀÌ ¾ïÁ¦µÇ°í Th2°¡ ¿ì¼¼ÇÏ¸é ¾Ë·¹¸£±â Áõ»óÀÌ ¹ßÇöµÈ´Ù. ÀÌ°ÍÀº ¹Ù²î°í ÀÖ´Ù.

 
100ÀÚÆò ¾²±â  À̸§: ÀÔ·ÂÀÏ:2024-03-29 
 
ÀÛ¼ºÀÚ : Lewis
Hookup Females Uses Free of charge Affairs?
A Fantastic Side to side Gain!

Free of charge hookup women sex on the internet is
the answer if you're tired with gonna bars and night clubs only to
be prevented, or even even worse, laughed at. I know what it's like because I've been there.

I found myself individual and eager in the working day -- I
essential a new companion -- however i continued striving because I needed hardly
any other decision. If you're a single gentleman who
wants to hookup with alluring ladies without likely
to those locations where females are alone, then this write-up might just change your
life. It will explain why internet dating on the internet is the
ideal substitute if you're a men that is too shy to approach a lovely woman inside a club or club.
ÀÛ¼ºÀÚ : Corazon
Hookup Girls Employs Totally free Matters? A Fantastic Horizontal Reward!


Free of charge hookup ladies dating on the internet is
the answer if you're tired of gonna night clubs and
organizations merely to be prevented, or
even a whole lot worse, laughed at. I know what it's like because I've been there.
I used to be solitary and needy back in the working day
-- I necessary a whole new partner -- but I kept on attempting because I had not one
other selection. If you're an individual guy who would like to hookup with attractive females without
going to those spots where the girls are by itself,
than the post may just make positive changes to life. It is going to clarify why online dating on-line is the ideal option if you're a guy
that is shy to technique a lovely girl in the club or group.
ÀÛ¼ºÀÚ : cbd washington dc
u2pRzt Major thankies for the article.Much thanks again. Want more.
ÀÛ¼ºÀÚ : Royal CBD
OsMCKW is green coffee bean extract safe WALSH | ENDORA
ÀÛ¼ºÀÚ : RoyalCBD.com
XgnB4u Very good article post.Really looking forward to read more. Keep writing.
ÀÛ¼ºÀÚ : Royal CBD
VkELKU Thank you ever so for you blog post.Really thank you! Fantastic.
ÀÛ¼ºÀÚ : Royal CBD
lW8ztU Respect for ones parents is the highest duty of civil life.
ÀÛ¼ºÀÚ : cbd washington dc
Qeg2dR Only wanna admit that this is invaluable , Thanks for taking your time to write this.
ÀÛ¼ºÀÚ : Aly Chiman
Hello there,

My name is Aly and I would like to know if you would have any interest to have your website here at pe.kr promoted as a resource on our blog alychidesign.com ?

We are in the midst of updating our broken link resources to include current and up to date resources for our readers. Our resource links are manually approved allowing us to mark a link as a do-follow link as well
.
If you may be interested please in being included as a resource on our blog, please let me know.

Thanks,
Aly
ÀÛ¼ºÀÚ : mia pron khalifa
GWEtow There is perceptibly a lot to identify about this. I consider you made some good points in features also.
ÀÛ¼ºÀÚ : suba suba
nHNIXv pretty valuable material, overall I believe this is worth a bookmark, thanks
ÀÛ¼ºÀÚ : tits tits tits
lf5fUu Pretty! This has been an extremely wonderful article. Thanks for providing this information.
ÀÛ¼ºÀÚ : tits tits tits
goIdUL pretty handy stuff, overall I feel this is well worth a bookmark, thanks
ÀÛ¼ºÀÚ : best pron
iVRCsX Ridiculous quest there. What happened after? Thanks!
ÀÛ¼ºÀÚ : pron best
HzdRbk Right now it looks like BlogEngine is the best blogging platform out there right now. (from what I ave read) Is that what you are using on your blog?
ÀÛ¼ºÀÚ : lucy ann
nG9fUM Thanks-a-mundo for the blog article.Really thank you! Cool.
ÀÛ¼ºÀÚ : this site
C0t41Y You, my pal, ROCK! I found exactly the information I already searched everywhere and simply couldn at find it. What an ideal web-site.
ÀÛ¼ºÀÚ : jeremy abrams
TkUjn8 Wow, wonderful blog layout! How long have you been blogging for? you made blogging look easy. The overall look of your site is fantastic, let alone the content!
ÀÛ¼ºÀÚ : free pron
rDQkmC Wow! Thank you! I always wanted to write on my blog something like that. Can I implement a part of your post to my blog?
ÀÛ¼ºÀÚ : Visit This Link
sWgN3T Wow that was odd. I just wrote an incredibly long comment but after I clicked submit my comment didn at appear. Grrrr well I am not writing all that over again. Anyhow, just wanted to say great blog!
ÀÛ¼ºÀÚ : useful source
PG1wD5 information you provide here. Please let
ÀÛ¼ºÀÚ : best pron
AT0VjV Wow! This could be one particular of the most helpful blogs We ave ever arrive across on this subject. Basically Fantastic. I am also an expert in this topic so I can understand your effort.
ÀÛ¼ºÀÚ : cuck your mom
GjN5Wc When are you going to post again? You really inform me!
ÀÛ¼ºÀÚ : fuck your mom
UTEJXd I was suggested this website by my cousin. I am not sure whether this post is written by him as nobody else know such detailed about my trouble. You are incredible! Thanks!
ÀÛ¼ºÀÚ : porn movies
Major thanks for the article post.Much thanks again. Really Cool.
ÀÛ¼ºÀÚ : mark photo
DHVDgC Looking forward to reading more. Great blog.Really looking forward to read more. Awesome.
ÀÛ¼ºÀÚ : coco ser vice
wMUrLG Woman of Alien Great work you have got carried out, this site is admittedly interesting with great facts. Time is God as method of retaining everything from going on at once.
ÀÛ¼ºÀÚ : cocoservice
YGFobL Wow, incredible blog layout! How long have you been blogging for? you made blogging look easy. The overall look of your web site is fantastic, as well as the content!
ÀÛ¼ºÀÚ : hKGVaSXuClKVeDUycyj
UAa8RY
ÀÛ¼ºÀÚ : PTdkolHqTfGqGBB
zuOcAw
ÀÛ¼ºÀÚ : fiverr crorkservice
s0FaU3 Spot on with this write-up, I truly believe this website requirements a lot much more consideration. I all probably be once more to read much much more, thanks for that info.
ÀÛ¼ºÀÚ : crorkservice seo
RuWG98 this web site and be up to date everyday.
ÀÛ¼ºÀÚ : crork fiverr
5L35Aw Really informative post.Much thanks again. Want more.
ÀÛ¼ºÀÚ : crorkservice fiver
Xub1eG When are you going to post again? You really entertain a lot of people!
ÀÛ¼ºÀÚ : seo servicess
yQL95i Merely a smiling visitant here to share the love (:, btw outstanding layout.
ÀÛ¼ºÀÚ : crorkzz mattz
7eUG9O I think this is a real great post.Really looking forward to read more. Awesome.
ÀÛ¼ºÀÚ : crorkservice fiverr
npAVMU Good day! I just want to give a huge thumbs up for the nice data you may have right here on this post. I will be coming again to your weblog for more soon.
ÀÛ¼ºÀÚ : crork work
CNJCFL It is in point of fact a great and helpful piece of information. I'm happy that you simply shared this useful info with us. Please keep us informed like this. Thanks for sharing.
ÀÛ¼ºÀÚ : matz crorkz
WpC9xQ Say, you got a nice article post.Much thanks again. Keep writing.
ÀÛ¼ºÀÚ : link building
rAZ6Zu Really appreciate you sharing this blog.Much thanks again. Really Great.
ÀÛ¼ºÀÚ : link building
qBpdso Major thankies for the article post.Thanks Again. Fantastic.
ÀÛ¼ºÀÚ : Finu
This post has helped me think things thrguoh
ÀÛ¼ºÀÚ : Leonice
Notnihg I could say would give you undue credit for this story.
ÀÛ¼ºÀÚ : Madalin
That's not just the best anwsre. It's the bestest answer!
ÀÛ¼ºÀÚ : Islania
Thought it wod'unlt to give it a shot. I was right.
ÀÛ¼ºÀÚ : Segey
An answer from an expert! Thanks for cognributint.
ÀÛ¼ºÀÚ : Kaderimse
Your anewsr was just what I needed. It's made my day!
ÀÛ¼ºÀÚ : Eliza
Whoa, whoa, get out the way with that good inrfomation.
ÀÛ¼ºÀÚ : Jaylen
A pleasingly rational awnesr. Good to hear from you.
ÀÛ¼ºÀÚ : Gracelynn
Oh yeah, fabuulos stuff there you!
ÀÛ¼ºÀÚ : Marsue
My hat is off to your astute cmoamnd over this topic-bravo!
 
 
°íÁ¤°Ë»ö :  ¾Ë·¹¸£±â°³·Ð  /  ¾Ë·¹¸£°Õ  /  ±â°üÁöõ½Ä  /  ¾ÆÅäÇÇÇǺο°  /  À½½Ä¾Ë·¹¸£±â  /  µÎµå·¯±â  /  ¾Ë·¹¸£±âºñ¿°  
Á¤º¸Á¦°ø¿øÄ¢¤ÓÁ¤º¸°øÀ¯¹æ¿î¿µ¿øÄ¢¤ÓÀúÀ۱ǰü·Ã¤Ó°³ÀÎÁ¤º¸º¸È£¿øÄ¢¤ÓÀ̸ÞÀϹ«´Ü¼öÁý°ÅºÎ¤Ó°íÁ¤ÇÊÁø±¸ÇÔ¤ÓºñÁ¯°ú »ç¸í
¸ðµç ±ÛÀº ÀúÀÛ±Ç ¹ýÀÇ º¸È£¸¦ ¹Þ´Â ¹Ù ¹«´Ü ÀüÀç. º¹»ç. ¹èÆ÷µîÀ» ±ÝÇÕ´Ï´Ù.